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V Zusammenfassung 
 
Giardiasis, verursacht durch Infektionen mit dem einzelligen, intestinalen Parasiten 
Giardia duodenalis (G. duodenalis), ist weltweit eine der häufigsten humanen Parasitosen. 
Die Symptomatik ist dabei vielseitig und reicht von akuten Durchfällen bis hin zu schwer 
behandelbaren chronischen Diarrhöen und Malabsorption. Darüber hinaus gibt es auch 
Patienten bei denen eine Infektion völlig asymptomatisch verläuft. Bislang konnte nicht 
geklärt werden, wodurch die Diversität im klinischen Krankheitsbild hervorgerufen wird. Es 
gibt keine eindeutig beschriebenen Virulenz- oder Pathogenitätsmarker. Es wird vermutet, 
dass potentielle G. duodenalis Virulenzfaktoren Enzyme sind, die während des Kontaktes des 
Erregers mit den Dünndarmepithelzellen sezerniert werden. Eines dieser Enzyme ist die 
Arginin Deiminase (ADI), die Arginin zu Citrullin umwandelt. 
Ziel der Arbeit war es die Bedeutung der Arginin Deiminase für die Wirt-Pathogen-
Interaktion zu untersuchen um herauszufinden, ob es sich bei dem Enzym um einen ersten 
molekular definierten Virulenz- und Pathogenitätsfaktor für G. duodenalis handelt. Der Fokus 
lag dabei zum einen auf der Untersuchung des Einflusses des Enzyms auf die 
Wirtsimmunzellen und zum anderen auf der Bestimmung der Sequenz- und funktionellen 
Variabilität des Enzyms in Parasitenisolaten. 
Da in der Maus gezeigt werden konnte, dass Dendritische Zellen (DC) in der 
Wirtsimmunantwort gegen Giardia Infektionen beteiligt sind, wurde die immunologische 
Wirkung der Parasiten ADI auf humane monozytäre DC (moDC) untersucht. Dabei zeigten 
die mit rekombinantem, katalytisch aktivem Enzym (Assemblage A) behandelten LPS-
stimulierten moDC eine Zunahme in der Tumornekrosefaktor-alpha (TNF-α)-Sekretion und 
eine Abnahme in der Freisetzung von Interleukin (IL)-10 und IL-12p40. Weiterhin war eine 
Abnahme des DC Reifungsmarker CD83 und des kostimulatorischen Liganden CD86 nach 
ADI Behandlung ersichtlich. Diese Veränderungen im Phänotyp als auch in der 
Cytokinsekretion der moDC ließen sich auf die durch das Enzym hervorgerufene 
Arginindepletion und/oder auf die Bildung der Metabolite, also Citrullin und NH4
+
, 
zurückführen. Weiterhin konnte gezeigt werden, dass Parasitenisolate verschiedener 
G. duodenalis Assemblage A-Subtypen, vermutlich durch die katalytische  Aktivität der ADI, 
die Stickstoffmonoxid-Bildung einer intestinalen Epithelzelllinie inhibiert. Diese beiden 
immunmodulatorischem Effekte deuten daraufhin, dass die ADI vom Parasiten genutzt wird 
um der Immunantwort des Wirts zu entgehen. 
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Um weitere Hinweise dafür zu finden, dass es sich bei der G. duodenalis ADI um einen 
Virulenzfaktor handelt, wurde die Variabilität in der kodierenden Sequenz des Enzyms in 
verschiedenen Parasitenisolaten analysiert. Anschließend erfolgte die funktionelle 
Charakterisierung des nativen (verschiedene Assemblage A-Subtypen) als auch des 
rekombinant aufgereinigten Enzyms (Assemblage A, B und E). Dabei zeigten sich 
Unterschiede in der Substrataffinität der ADI für Arginin, sowohl zwischen unterschiedlichen 
Assemblage A-Subtypen als auch unterschiedlichen Assemblage-Klassen. Erste Hinweise auf 
eine Korrelation zwischen Variation in der Primärstruktur und Enzymfunktion konnten 
beobachtet werden. 
In dieser Arbeit konnte gezeigt werden, dass die G. duodenalis Arginin Deiminase als 
potentieller Virulenzfaktor die Wirtsimmunität beeinflusst und somit als Target für die 
Entwicklung neuer Medikamente und Impfstrategien in Frage kommen könnte. 
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VI Summary 
 
Giardia duodenalis (G. duodenalis) is an intestinal protozoan parasite that infects humans and 
other mammals as well. It causes giardiasis, one of the most prevalent parasitic diseases 
worldwide with symptoms ranging from asymptomatic carrier stage to chronic diarrhea. So 
far, little is known concerning host-parasite interaction, in particular what determines the 
parasite’s pathogenicity. Several potential virulence factors, among them the 
arginine deiminase (ADI) that hydrolyzes arginine into citrulline and NH4
+
, are discussed. 
The ADI was identified to be released upon contact with intestinal epithelium by Giardia 
trophozoites and was recognized as an immunoreactive protein during acute human giardiasis.  
Aim of the study was to identify potential roles of G. duodenalis ADI in the host-parasite 
interplay by analyzing the enzyme’s impact on host immune cells and to functionally 
characterize its genotypic variation.  
As dendritic cells (DC) are known to be involved in controlling giardial infection in mice, the 
influence of G. duodenalis ADI on human monocyte-derived DC (moDC) was investigated. 
Treatment of LPS-stimulated cells with recombinant ADI of assemblage A significantly 
increased tumor necrosis factor alpha (TNF-α) as well as decreased interleukin-10 (IL-10) and 
IL-12p40 secretion. It also reduced the upregulation of surface CD83 and CD86 molecules, 
which are involved in cell-cell interactions. These immunomodulatory changes in DC 
response were due to arginine depletion and the formation of reaction products, in particular, 
ammonium ions. Furthermore, trophozoites of different assemblage subtypes were shown, 
probably due to consumption of arginine by ADI, to reduce nitric oxide formation by 
intestinal epithelial cells in vitro. These observations underlined the presumption that ADI, 
like other arginine-depleting pathogen enzymes, is used by Giardia to evade host immune 
effector mechanisms.  
By sequencing, variation in the ADI coding sequence of different G. duodenalis isolates being 
collected in a Giardia biobank was analyzed. Subsequently, functional genetics were 
performed with native ADI of different assemblage A subtypes expressed by these strains as 
well as with purified, recombinant ADI of assemblage A, B and E.  First indications of a 
correlation between enzyme function and variation of the protein primary structure were 
noticed. 
In this report, G. duodenalis ADI was identified to have a direct impact on host immunity and 
thus the enzyme might be a new target for future drug or vaccine design against giardial 
infection.
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1 Introduction 
 
1.1 Giardia - a smiling parasite 
 
Giardia is a genus of intestinal protozoan parasites that was first observed by 
van Leeuwenhoek in 1681 (Boreham et al, 1990). They belong to the phylogenetic group of 
Diplomonadida that are characteristically binucleated and lack aerobic mitochondria and 
stacked Golgi. Giardia is an aerotolerant anaerobe that contains mitochondrial relicts, the 
mitosomes (Adam, 2001; Regoes et al., 2005). The parasite exists in two forms: the dormant, 
infective cysts and the vegetative, disease-causing trophozoites. Cysts are egg-shaped and 
approximately 8-12 µm long and 5-9 µm wide. They are enclosed by a 0.3-0.6 µm thick cyst 
wall, that has a fibrillous structure and is composed of β(1-3)-N-acetyl-D-galactosamine, at 
least three cyst wall proteins and a subjacent double inner membrane (Erlandsen et al., 1996; 
Gerwig et al., 2002; Sun et al., 2003;  Ankarklev et al., 2010). In contrast, trophozoites are 
bilaterally symmetrical with a teardrop shape and are approximately 15 µm in length, 5 µm in 
width and 5 µm thick (Dawson, 2010) (Fig. 1). The ventral side is flat whereas the dorsal side 
is convex.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Morphology of Giardia trophozoites 
 (A) Schematic and (B) Scanning electron micrograph (SEM) of Giardia trophozoite structure. A ventral view of 
a Giardia trophozoite shows its teardrop shape with nucleus (N), median body (mb), funis (fn), ventral disc (vd) 
and four flagellar pairs (afl = anterior flagella, pfl = posteriorlateral flagella, vfl = ventral flagella, cfl = caudal 
flagella). Scale bar = 5 μm. (modified, Dawson and House 2010) 
 
 
Giardia has a complex cytoskeleton. Striking microtubule-based structures are the eight 
flagella organized in four bilaterally symmetrical pairs (anterior, caudal, posteriolateral, 
ventral) that provide motility to the parasite, the ventral adhesive disc that allows attachment 
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to the intestinal villi as well as the median body and the funis with currently unknown 
function (Elmendorf et al., 2003). Characteristically, the location of the median body let the 
parasite “smile” when visualized by Giemsa staining. 
 
 
1.2 Epidemiology of giardiasis  
 
Giardia is distributed globally and infects a broad range of vertebrates. The species 
Giardia duodenalis (G. duodenalis) is the causative agent of giardiasis, one of the most 
prevalent parasitic diseases in humans worldwide. Due to its ill-influence on health, the 
parasite is included in the WHO Neglected Disease Initiative (Saviolo et al., 2006). It is 
estimated that worldwide 280 million people suffer giardiasis annually (Lane and Lloyd, 
2002). Thereby, its regional prevalence varies. According to the CDC (2013), in developed 
countries nearly 2% of the adults and 6%-8% of children are affected by the disease. In 
developing countries, where giardial infections are very common in children (Nkrumah and 
Nguah, 2011), approximately 33% of people have had suffered from giardiasis.  
In Germany, giardiasis is a notifiable disease. The average incidence between 2001 and 2010 
was 4.7 cases per 100000 populations (RKI-Infektionsepidemiologisches Jahrbuch, 2011). In 
2011, 4258 cases of giardiasis were reported with an incidence of 5.2 cases per 
100000 populations. The infections were acquired autochthonous, but also travelling into 
foreign countries (e.g. India, Turkey) was noticed as a source of infection 
(RKI-Infektionsepidemiologisches Jahrbuch, 2012). In 2010 and 2011, reported giardiasis 
cases were constant over the whole year and did not rise in late summer 
(Infektionsepidemiologisches Jahrbuch, 2011 and 2012). This is in contrast to the 
United States, where in 2006-2008 giardiasis cases were two times higher between June to 
October than between January to March (CDC, 2010). In Germany, the disease had the 
highest incidence rates among young children (age 1-4) followed by a group of adults 
between 20-49 years in 2011 (RKI-Infektionsepidemiologisches Jahrbuch, 2012).  
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1.2.1 Classification and molecular characterization of Giardia 
 
G. duodenalis is found in many mammals, including humans (Thompson, 2000). Its 
phylogenic investigation based on the nucleotide sequence analysis of several housekeeping 
genes (e.g. β-giardin, glutamate dehydrogenase, triosephosphate isomerase) and the small-
subunit rRNA gene, revealed the existence of eight major genetic groups, termed assemblages 
A-H (Monis et al., 2003; Cacciò and Ryan, 2008; Lasek-Nesselquist et al., 2010). Some of 
them can be further classified into subtypes (e.g. AI, AII, AIII, AIV) (Amar et al., 2002; 
Cacciò et al., 2002). Each assemblage is known to infect certain host species, but among them 
only assemblage A and B are found in humans (Tab. 1). Globally, assemblage B is identified 
to be prevalent in human patients, except certain regions of South America and Mexico 
(Cacciò and Ryan, 2008; Jerlström-Hultqvist et al., 2010). However, a mixture of genotypes 
within a host can be observed from time to time, e.g. due to ingestion of genetically different 
Giardia cysts or re-infection with Giardia species carrying another genotype (Geurden et al., 
2009; Levecke et al., 2009; Sprong et al., 2009). An additional explanation for this 
phenomenon is the occurrence of allelic sequence heterogeneity and/or genetic recombination 
that was observed to be more common in assemblage B then A (Jerlström-Hultqvist et al., 
2010).    
 
 
Table 1: Molecular characterization of G. duodenalis 
Assemblage Some species commonly infected 
AI 
humans and animals (cats, dogs, livestock, deer, muskrats, beavers, 
voles, guinea pigs, ferrets) 
AII humans (more common than A-I) 
AIII, AIV exclusively animals 
B humans and animals (livestock, chinchillas, beavers, marmosets, rodents) 
C, D dogs, coyotes 
E alpacas, cattle, goats, pigs, sheep 
F Cats 
G Rodents 
H Seals 
(modified CDC, 2013) 
 
Already in 1979, the WHO considered giardial infection a zoonosis (WHO, 1979). 
Nevertheless, the role of animals as reservoir for the transmission of human giardiasis remains 
subject of current studies. Thereby, especially domestic pets, farm animals, and wild 
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mammals that are commonly infected with the parasite, could be a serious source to cause 
infection in humans. First hints of zoonotic transmission of assemblage A and B between 
certain animals (e.g. cats, dogs) and humans were observed (Sprong et al., 2009; Ballweber et 
al., 2010; Lebbad et al., 2010; Lebbad et al., 2011; McDowall et al., 2011) confirming the 
potential of G. duodenalis to be a zoonotic organism.  
So far, three distinct G. duodenalis isolates were analyzed on their molecular level in detail. 
In 2007, the 11.7 Mbp WB-assemblage A G. duodenalis genome with approximately 4800 
predicted protein encoding genes was published (Morrison et al., 2007), followed in 2009 
with those of GS-assemblage B (Franzén et al., 2009). The sequenced genomes of these both 
major human assemblages showed an average nucleotide identity of 77% and an amino acid 
identity in 4300 orthologous proteins of only 78%. Due to these genetic differences, both 
genotypes were discussed to be two separate species (Nash et al., 1985; Franzén et al., 2009; 
Monis et al., 2009). This aspect was strengthened in 2010 with the sequencing of the 
P15-assemblage E G. duodenalis genome isolated from pig. The comparison of all three 
isolates identified a highly conserved set of core genes (4557 genes, 91% of genome). 
Genomic differences were found in Giardia-specific gene families, e.g. variant-specific 
surface proteins (VSPs). The average amino acid identity between assemblage E and B was 
81% and, surprisingly, between E and A was 90 % revealing a closer relationship of 
assemblage A and E (Franzén et al., 2009; Jerlström-Hultqvist et al., 2010). 
 
 
1.3 Life cycle of G. duodenalis 
 
G. duodenalis is transmitted by ingestion of cysts found on surfaces, in soil, food, and 
(drinking and recreational) water that have been contaminated with feces from infected 
humans/animals or by the fecal-oral route (hands or fomites) (Fig. 2). The infectious dose 
with 10 to 100 parasites is low (Farthing, 1997). After swallowing, the giardial cysts pass the 
stomach of the host and become exposed to low pH due to gastric acids that are thought to 
initiate a cell differentiation process termed excystation (Gillin et al., 1996). An infective, 
metabolically inactive cyst is transformed into a short-lived excyzoite stage. During this 
division process, metabolism within the cell is activated, gene expression is upregulated and 
the adhesive disc starts to assemble. The excyzoite undergoes cytokinesis twice (without 
intervening S phases) and finally liberates four motile trophozoites containing two diploid 
nuclei (Bernander et al., 2001). Once arrived in the lumen of the duodenum, trophozoites start 
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to reproduce. The generation time of the parasite is 6-12 hours in vitro (Ankarklev et al., 
2010). Both diploid nuclei divide into four diploid nuclei and are separated by longitudinal 
binary fission (Yu et al., 2002). Earlier, the two nuclei of one trophozoite were thought to be 
equal in size and the amount of DNA (Kabnick and Peattie, 1990; Yu et al., 2002) being 
organized on five major chromosomes (Adam, 2001). However, studies revealed differences 
in chromosome size and number in both nuclei (Tůmová et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                        
 
 
 
 
 
 
 
 
                                    CDC/Dr. Stan Erlandsen (1988)          CDC/Dr. Stan Erlandsen (1999) 
 
Figure 2: Life cycle of G. duodenalis 
(A) represents a  schematic overview about the life stages of G. duodenalis. (B) and (C) shows in SEM Giardia 
trophozoites that are grouped on the intestinal mucosal surface after infection. In (C) circular lesions on the 
intestinal epithelial surface resulting from the strong attachment of the parasite’s ventral adhesive disk are 
noticeable. 
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In the small intestine, trophozoites can attach to the mucosa without invading epithelial cells 
and can cause outbreak of the disease with its characteristic clinical symptoms. The entire 
excystation process is very fast and takes no longer than 15 minutes in vitro (Hetsko et al., 
1998). The second developmental transition is initiated when the parasite passes toward the 
colon and is exposed to host specific factors e.g. high levels of bile or basic pH (Gillin et al., 
1996). During this process, named encystations, replicating trophozoites are converted into 
nonmotile, metabolically inactive cysts. In the early phase trophozoite’s flagella reform and 
shape rounds up, cyst wall proteins are enclosed into vesicles and transported to the 
developing cyst wall, the adhesive disc disassembles, and metabolism activity becomes 
downregulated (Ankarklev et al., 2010). After DNA replication, the cell cycle is exit in the 
G2 stage and the developed excyzoite contains two tetraploid nuclei that subsequently divide 
into four diploid nuclei during the late phase of the encystation process (Bernander et al., 
2001; Svärd et al., 2003; Reiner, 2008; Ankarklev et al., 2010). After additional DNA 
replication, a robust, infectious cyst enclosed by a thick cell wall is formed that contains four 
tetraploid nuclei (and a cyst ploidy of 16n) and ribbon-like microtubule structures (Bernander 
et al., 2001). Most commonly in nondiarrheal feces, these cysts are then released into the 
environment in where they can survive.  
 
 
1.4 Pathology of a giardial infection 
 
Giardiasis causes a broad range of intestinal symptoms. In its acute phase occurring 
approximately one to three weeks post-infection (Gardner and Hill, 2001), patient can suffer 
from flatulence, stomach or abdominal cramps, nausea, greasy stool and diarrhea. Chronic (or 
recurrent) infections can lead to dehydration, weight loss and malabsorption (e.g. failure to 
absorb vitamin B12) (Olivares et al., 2002). It was reported that in a G. duodenalis 
hyperendemic area, 98% of the drug-cured children became reinfected within a half year 
(Gilman et al., 1988). This is dramatic because giardiasis effects physical and mental growth 
of infected children (Berkman et al., 2002; Botero-Garcés et al., 2009). Furthermore, giardial 
infections are discussed to be related to arthritis (Carlson and Finger, 2004), allergies 
(Bayraktar et al., 2005), chronic fatigue (Hanevik et al., 2012) and irritable bowel syndrome 
(Hanevik et al., 2009; Wood, 2011).  
The duration of infection and characteristic symptoms are highly variable. Giardiasis is often 
self-limiting with duration of two to four weeks (Flanagan, 1992). Currently, the reasons for 
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half of the infected people never developing any symptoms and for the variance of the period 
of symptoms from two to six weeks to the point of chronic infections are still unclear.  
Several drugs are available for the treatment of giardial infection. Metronidazole (MTZ), a 
nitroimidazole drug, that cures patient with an efficacy of 80-95% is most widely used 
(Gardner and Hill, 2001). Treatment success depends on medical history, nutritional and 
immune status of the patient (Upcroft and Upcroft, 1993; Müller et al., 2008; Solaymani-
Mohammadi et al., 2010). Thus, it is sometimes necessary to increase the doses, extend the 
duration of treatment, or to give an alternative drug or a combination of drugs. For example, 
patients that have medical intolerance, or patients that are infected with resistant strains, can 
be treated with quinacrine, alone or in combination with nitroimidazole (Escobedo and 
Cimerman, 2007; The Medical Letter, 2010). 
 
 
1.5 Immunology of giardial infection  
 
The variability in clinical outcome in giardiasis is less understood. Factors being linked to 
disease outbreak are host´s clinical and nutritional status, age and immune response 
(Roxström-Lindquist et al., 2006).  Thereby, especially host immune response and parasite 
defense mechanism interact in close relation. After introducing the mucosal immune response, 
host and parasitic factors influencing the pathology of giardial infections shall be explained in 
the following chapter. 
 
 
1.5.1 The mucosal immune system 
 
The mucosal immune system (MIS) is a unique part of the human immune system that 
protects mucous membranes covering i.a. the respiratory, gastrointestinal and urogenital tract 
from colonization and invasion of pathogens. It prevents the uptake of undegraded antigens 
and the development of a potentially harmful immune response against these antigens when 
they enter the body interior inadvertently (Holmgren and Czerkinsky, 2005).  
Within this study, it is focused on the MIS of the gastrointestinal tract, especially in the small 
intestine. The intestinal mucosa consists of a single-layer epithelium that is arranged in villi, 
underlined by the lamina propria and covered by mucus and antimicrobial products (McGhee 
and Fujihashi, 2012). The mucosal epithelium is important for the host defense machinery by 
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providing a natural barrier and innate immunity. It is formed by columnar epithelial cells 
termed enterocytes absorbing nutrients and secreting immunoglobulins, goblet cells secreting 
mucin and Paneth cells secreting chemokines, cytokines, and anti-microbial peptides named 
α-defensins (Nagler-Anderson; 2001; Porter et al., 2002; McGuckin et al., 2011).  
The MIS is a complex network that is composed of immune-inductive sites including the gut-
associated lymphoid tissues (GALT) as well as immune-effector sites including the lamina 
propria lymphocyte compartments. The GALT include i.a. the Peyer's patches (PPs) and the 
Mesenteric lymph nodes (MLNs). The PPs are covered by microfold cells that sample 
antigens from the gut lumen and deliver them to underlying antigen-presenting cells (APC), 
including dendritic cells (DC) (McGhee and Fujihashi, 2012). DC were also shown to directly 
capture antigens by projecting dendritic extensions between epithelial cells into the lumen of 
the gut (Rescigno et al., 2001; Chieppa et al., 2006).  
Through a combination of signals such as the recognition of microbe-associated molecular 
patterns by pattern recognition receptors and cytokine signals, DC become stimulated to 
mature and migrate to peripheral lymph nodes to initiate antigen-specific immunity 
(Pulendran et al., 2001; Münz et al., 2005). Maturing DC upregulate cell surface markers (e.g. 
MHC, CD83, CD86) and release cytokines (e.g. IL-12, IL-10, TNF-α) to enable 
communication with and activation of T- and other immune cells (Banchereau et al., 2000). 
After initiation of the adaptive immune response, stimulated B and T cells pass the MLNs and 
are further transported via the blood stream to the mucosal effector sites of the gut where they 
are differentiated into memory or effector cells. Among others, in consequence of the adaptive 
mucosal immune response, CD4+ T cells support the development of IgA-producing plasma 
cells. Secretory IgA antibodies are transported across ECs by a process of transcytosis 
(McGhee and Fujihashi, 2012).  
 
 
1.5.2 Host defense mechanisms 
 
The host defense mechanism against infection with Giardia includes nonimmunological as 
well as immunological characteristics. In the beginning of the infection the parasite has to 
overcome natural barriers. For example, a permanent attachment of the parasite to the 
intestinal surface is hindered by constantly regeneration of the intestinal cells. To prevent 
elimination by peristalsis, Giardia has to move and re-attach continuously (Roxström-
Lindquist et al., 2006). It was also shown that mucin, as component of the mucus produced by 
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the epithelial tissue, may inhibit Giardia trophozoite attachment in vitro (Roskens and 
Erlandsen, 2002). Furthermore, probiotic bacteria of the natural gut flora (e.g. Lactobacillus 
johnsonii, Enterococcus faecium, Lactobacillus rhamnosus) were identified to positively 
affect the anti-Giardia immune response in vivo (Benyacoub et al., 2005; Humen et al., 2005; 
Goyal and Shukla, 2013).  
Typically, an infection with enteric pathogens induces a mucosal immune response. Beside 
epithelial cells, also other cells of the innate immunity like Mast cells and DC as well as cells 
of the adaptive immune response like B and T cells were investigated concerning their 
function in giardial infection control.  
As a part of the innate immunity, intestinal epithelial cells (IEC) secrete antimicrobial 
peptides like defensin or lactoferrin that have anti-giardial activity in vitro (Aley et al., 1994; 
Turchany et al., 1995), and form nitric oxide (NO) that inhibits growth and differentiation 
processes, but  do not affect variability of G. duodenalis in vitro (Eckmann et al., 2000). 
Ordinary, in host immune response inflammation processes are caused by secretion of several 
chemokines and cytokines. During giardial infection only mild inflammation is observed 
(Oberhuber et al., 1997). IL-8 is one of the most important cytokines secreted during 
inflammatory response by host epithelial cells in the gut (Yomogida et al., 2008). Its level 
does not rise after G. duodenalis infection of human intestinal epithelial cell lines in vitro. 
Other proinflammatory cytokines like IL-6, TNF-α and the immunoregulatory cytokines 
IFN-γ are not upregulated as well (Roxström-Lindquist et al., 2005). However, IL-6 and 
IFN-γ were noticed to be involved in parasite clearance mechanism in mice (Venkatesan et 
al., 1997; Bienz et al., 2003; Zhou et al., 2003). Thus, other cells of the innate immune system 
like APC might be involved in this cytokine response. The impact of APC on giardial 
infection is less understood. In gerbils, mast cells were identified to accumulate in the small 
intestine during giardial infection (Leitch et al., 1993; Hardin et al., 1997). In mice, the IL-6 
production by these cells was suggested to be important for controlling giardial infection (Li 
et al., 2004). In contrast, a recent study in mice suggested IL-6 production by DC to be 
important for anti-Giardia immune response (Kamda et al., 2012).  
Furthermore, the adaptive immunity was noticed to play a role in defense against Giardia. It 
was shown that T-cell-deficient mice infected with G. duodenalis could not eliminate the 
infection and that depletion of CD4+ T cells results in development of chronic giardiasis 
(Singer and Nash, 2000). Recent studies confirmed CD4+ T cells to be required for 
controlling giardial infection (Solaymani-Mohammadi and Singer, 2011). Furthermore, 
T cells were identified to be involved in causing mucosal alterations in murine giardiasis 
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(Gillon et al., 1982; Ferreira et al., 1990; Farthing, 1993; Scott et al., 2000). Therefore, both, 
CD4+ and CD8+ T cells, were responsible for increased numbers of intraepithelial 
lymphocytes whereas CD8+ alone caused microvillous shortening (Scott et al., 2004). It is 
known that humoral immune response plays a crucial role in parasite clearance mechanism. 
While the early phase of giardial infection is characterized by the above explained B-cell-
independent mechanisms, the later phase, starting two weeks post-infection, is antibody-
dependent in mice (Eckmann, 2003). Infection of humans with G. duodenalis leads to 
secretion of anti-Giardia secretory IgA in serum (Nash et al., 1987; Palm et al., 2003), 
mother´s milk and saliva (Téllez et al., 2005). It was shown that IgA-deficient, but not IgM-
deficient, mice were not able to eradicate Giardia spp. infections (Langford et al., 2002). 
Furthermore, children born to mothers lacking anti-Giardia antibodies in their breast milk had 
a higher risk to contract giardial infection (Téllez et al., 2003).  
To sum up, natural barriers like mucus, intestinal microbiota and peristalsis, innate immunity 
with defensin secretion and NO formation by IEC, cytokine production of mast cells and DC 
as well as the adaptive immunity including T cells response and antibody production are 
involved in the host defense machinery against Giardia (Roxström-Lindquist et al., 2006).   
 
 
1.5.3 Parasite defense strategies 
 
The mechanisms by which G. duodenalis causes clinical symptoms are still unclear. The 
parasite is not invasive and secretes no known toxins. Giardial infections were shown to affect 
the activity of gut enzymes like disaccharidases in gerbils (Belosevic et al., 1989; Buret et al., 
1991). Furthermore, giardial infections cause damage of the mucosal surface, by shortening of 
crypts and microvilli, in the small intestine that result in malabsorption of electrolytes, 
nutrients, and water (Buret et al., 1992; Farthing, 1997; Scott et al., 2000; Scott et al., 2004). 
Furthermore, strain-dependent G. duodenalis-induced apoptosis of human IEC that leads to 
disruption of tight junctions and increased intestinal permeability was shown in vitro (Chin et 
al., 2002; Koh et al., 2013). Thereby, apoptosis was recognized to be induced by the parasite 
via the intrinsic and the extrinsic apoptotic pathways in IEC (Panaro et al., 2007). In vivo 
studies investigating duodenal biopsy from chronically infected patients confirmed epithelial 
barrier dysfunction due to changes in tight junctions and increased apoptosis (Troeger et al., 
2007). Furthermore, in vitro studies investigating the interaction of murine bone marrow-
derived DC with Giardia trophozoites or Giardia extracts suggest interferences of the parasite 
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with the host innate immunity due to changing cytokine secretion and surface marker 
expression (Kamda and Singer, 2009).  
Studies from the last decades give first hints in parasite defense that implicate the existence of 
virulence factors.  Virulence factors are defined as features (e.g. toxins, enzymes, metabolites, 
cell surface molecules) of a certain pathogen that are directly disease-causing or indirectly 
involved in the establishment of an infection. This includes especially properties of the 
microbe to enter, replicate and persist within the host, e.g. due to strategies for attachment to 
the host and/or evasion and suppression of the host immune response (Cross, 2008). 
Molecularly, virulence factors can have genotypic variation among different environmental 
isolates.  
For G. duodenalis several virulence factors are discussed. For example, the ventral disc 
ensures motility to Giardia. It allows the parasite to attach to the intestinal surface and to 
differentiate into cysts to survive within and outside the host. One strategy of G. duodenalis is 
to evade the host humoral immunity by antigenic variation of its surface proteins (Aggarwal 
and Nash, 1988; Nash et al., 1988). The major antigens covering the outer surface of the 
parasite are VSPs that were targeted by the host’s antibodies. They are cysteine-rich and vary 
in size from 20 to 200 kDa (Rópolo et al., 2005). A VSP consist of a variable amino terminus 
and a conserved, cytoplasmatic carboxyl terminus with a CRGKA motif (Ankarklev et al., 
2010). VSPs are encoded by approximately 200 different genes, but only one VSP is 
expressed per trophozoites and this usually dominates within a population (Prucca et al., 
2011). The changing of VSP expression that leads to antigenic variation (Nash, 2002) is, in 
vivo (von Allmen et al., 2004) and in vitro (Svärd et al., 1998; Carranza et al., 2002), partly 
initiated by cell differentiation. Beside the function of escaping the host immune system, 
VSPs are also known to protect the parasite against proteases in vitro (Nash et al., 1991). 
Furthermore, they were identified to be immunoreactive in milk samples from lactating 
women living in an endemic region. In these samples and in serum samples from patients with 
acute giardiasis living in a nonendemic area further immunoreactive proteins like the arginine 
deiminase (ADI), ornithine carbamoyl transferase (OCT) and enolase were noticed (Palm et 
el., 2003; Téllez et al., 2003). These three enzymes were shown to be released by the parasite 
upon contact with IEC in vitro. Studies with G. duodenalis-infected mice could only confirm 
the release of ADI and enolase in intestinal luminal fluid in vivo (Ringqvist et al., 2008).   
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1.5.3.1 G. duodenalis ADI and its function 
 
The ADI (EC 3.5.3.6) is encoded by the ArcA gene that is located on chromosome 3 of 
G. duodenalis strain WB-C6 and contains no introns. Expression of the 1743 bp open reading 
frame leads to the synthesis of the 64 kDa enzyme that forms in its native form a homodimer 
(Knodler et al., 1998). In vitro, ADI is localized in the cytoplasm of the trophozoites whereas 
during co-incubation with IEC the enzyme is accumulated to the most anterior part of the 
parasite (Ringqvist et al., 2008). The ADI is involved in the energy metabolism of the 
parasite. It converts free L-arginine into L-citrulline and ammonia during the first step of the 
arginine dihydrolase (ADH) pathway. The formed L-citrulline is then further metabolized by 
the OCT into L-ornithine and carbamoyl phosphate that is used to generate ATP by the 
carbamate kinase (Schofield et al., 1990; Schofield et al., 1992). Beside its function in the 
metabolic pathway, G. duodenalis ADI was suggested to play a role in controlling antigenic 
variation via VSP citrullination. Touz et al. (2008) identified the enzyme to have a peptidyl-
arginine deiminase (PAD) activity that leads to conversion of the arginine residue within the 
CRGKA motif of VSPs into citrulline. Additionally, they showed an impact of the enzyme in 
the encystation process. Interaction studies revealed an early upregulation of ADI gene 
expression, but a later downregulation in Giardia trophozoites after contact with IEC in vitro 
(Ringqvist et al., 2011). Furthermore, in vitro studies showed that G. duodenalis (Eckmann et 
al., 2000) as well as recombinant G. duodenalis ADI (Ringqvist et al., 2008) inhibits NO 
formation of human IEC by consumption of free arginine, the substrate of the epithelial NO 
synthase (NOS) to form NO. Arginine depletion by the parasite’s ADI was also shown to 
reduce proliferation of human IEC lines in vitro (Stadelmann et al., 2012). 
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1.6 Aim of the study 
 
Giardiasis, caused by the parasite G. duodenalis, is a global public health problem, especially 
due to common occurrence of chronic infections. Currently, less is known about virulence and 
pathogenicity mechanisms of G. duodenalis and their role in disease outcome. Certain 
antigens were indentified to be immunodominant in human body fluids and several were 
additionally found to be released after host-pathogen contact in vitro. These immunoreactive 
proteins, such as ADI, are considered to be potential virulence factors and therefore might 
play an important role in host-pathogen interaction. To examine the function of G. duodenalis 
ADI in human giardiasis, the following report was divided into two major parts: 
 
 
1. Role of G. duodenalis ADI in host immune response and parasite defense mechanism 
To explore the role of ADI in host-pathogen interaction, the enzyme’s impact on different cell 
types important in mucosal immunity and on host protein modification was studied.  
Thus, human monocyte-derived DC (moDC) were treated with recombinant ADI 
(assemblage A) to analyze host immunological features like cytokine expression and cell 
surface markers. Furthermore, a human intestinal cell line was treated with different human 
G. duodenalis patient isolates to investigate a strain-dependent impact on host NO production. 
Possible posttranslational modification of host proteins by ADI’s previously described PAD 
activity, i.e. citrullination of intrapeptidic arginine, was analyzed.  
 
 
2. Identification of G. duodenalis ADI sequence and functional variability in human 
clinical isolates  
To support the hypothesis of ADI being a virulence factor, its sequence-variation in the 
natural human G. duodenalis population was analyzed. Sequence variability of the enzyme 
was functionally characterized to identify a potential correlation between primary structure 
and function. Thus, the substrate affinity for arginine was determined in enzyme kinetics for 
native ADI (assemblage A-subtypes) from human patients suffering giardiasis and the 
recombinant enzyme (assemblage A, B and E). 
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2 Material  
 
2.1 Chemicals 
 
Acetic acid Merck, Darmstadt, G 
Acetone  Roth, Karlsruhe, G 
Agarose  Biozym, Hessisch Oldendorf, G 
Ammonium chloride  Sigma, Steinheim, G 
Ammonium ferric citrate  Sigma, Steinheim, G 
Ammonium persulfate (APS)  Sigma, Steinheim, G 
Ampicillin  Roth, Karlsruhe, G 
L-Arginine  Merck, Darmstadt, G 
L-Ascorbic acid  Sigma, Steinheim, G 
Bacto agar  Oxoid, Wesel, G 
Bacto
™
 tryptone  BD, Heidelberg, G 
Bacto
™
 yeast extract BD, Heidelberg, G 
Bile from bovine Sigma, Steinheim, G 
Bisbenzimide  Sigma, Steinheim, G 
Bovine serum albumin (BSA)  Roth, Karlsruhe, G 
Bromophenol blue  Sigma, Steinheim, G 
Calcium chloride (CaCl2)  Sigma, Steinheim, G 
L-Citrulline  Sigma, Steinheim, G 
L-Cysteine Sigma, Steinheim, G 
Coomassie Brilliant Blue R-250  Roth, Karlsruhe, G 
Deoxynucleoside triphosphates (dNTP) Roth, Karlsruhe, G 
Diacetyl monoxime  Sigma, Steinheim, G 
Dimethyl sulfoxide (DMSO)  Sigma, Steinheim, G 
Dipotassium phosphate (K2HPO4)  Sigma, Steinheim, G 
Disodium hydrogen phosphate (Na2HPO4)  Sigma, Steinheim, G 
Dithiothreitol (DTT)  Roth, Karlsruhe, G 
Ethylenediaminetetraacetic acid (EDTA)  Roth, Karlsruhe, G 
EDTA-free protease inhibitor cocktail                                      Roche, Mannheim, G 
Entellan
®
  Merck, Darmstadt, G 
Fetal calf serum (FCS); dialyzed Biochrom, Berlin, G 
FCS (for DC/Caco-2 cultivation) Biochrom, Berlin, G 
FCS (for Giardia cultivation) Sigma, Steinheim, G 
Ferric chloride (FeCl3)  Sigma, Steinheim, G 
Ficoll-Paque
™
 Plus GE Healthcare, Munich, G 
GelGreen
™
   Biotium, Hayward, USA 
Glucose Sigma, Steinheim, G 
L-Glutamine  Biochrom, Berlin, G 
Glycerol  Roth, Karlsruhe, G 
Glycine  Roth, Karlsruhe, G 
Granulocyte-macrophage colony-stimulating  Bayer, Seattle, USA 
factor (GM-CSF), human     
Hepes (4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid) Sigma, Steinheim, G  
Hepes (for cell culture) Biochrom, Berlin, G 
H6-CRGKA  Genscript, Piscataway, USA 
Imidazole                                                                                  Merck, Darmstadt, G  
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IFN-γ, human  eBioscience, Frankfurt, G 
IL-1β, human  ImmunoTools, Friesoythe, G 
IL-4, human   R&D Systems, Wiesbaden- 
 Nordenstadt, G 
Kanamycin  Sigma, Steinheim, G 
LPS (E. coli 026:B6)  Sigma, Steinheim, G 
Methanol  Roth, Karlsruhe, G 
Milk powder  Roth, Karlsruhe, G 
Minimum essential medium (MEM) with Earle’s Salts PAA, Pasching, A 
Mowiol 4-88  Roth, Karlsruhe, G 
Nonessential Amino Acid Solution (NEAA)  Life technologies, Darmstadt, G 
L-Ornithine  Sigma, Steinheim, G 
Paraformaldehyde (PFA)  Roth, Karlsruhe, G 
Penicillin/Streptomycin (for cell culture)  PAA, Pasching, A 
Peptone from casein Merck, Darmstadt, G 
Phosphoric acid (H3PO4)  Sigma, Steinheim, G 
Potassium chloride (KCl)  Merck, Darmstadt, G 
Potassium dihydrogen phosphate (KH2PO4) Sigma, Steinheim, G 
Rapamycin  Sigma, Steinheim, G 
Roswell Park Memorial Institute (RPMI) medium 1640  Sigma, Steinheim, G 
Rotiphorese
®
 Gel 30 (37.5:1)  Roth, Karlsruhe, G 
RPMI 1640 medium (arginine-free) PAN-Biotech, Aidenbach, G 
Sodium chloride (NaCl)                                                        Sigma, Steinheim, G 
Sodium deoxycholate  Sigma, Steinheim, G 
Sodium dodecyl sulfate (SDS)  Sigma, Steinheim, G 
Spectinomycin  Sigma, Steinheim, G 
Sulfuric acid  Merck, Darmstadt, G 
Tetracycline Merck, Darmstadt, G 
Tetramethylethylenediamine (TEMED)  Roth, Karlsruhe, G 
TNF-α, human  ImmunoTools, Friesoythe, G 
Thiosemicarbazide  Sigma, Steinheim, G 
Trichloroactetic acid  Merck, Darmstadt, G 
Tris(hydroxymethyl)aminomethane (Tris) Roth, Karlsruhe, G 
Tris-HCl  Roth, Karlsruhe, G 
Triton X-100  Sigma, Steinheim, G  
Trypsin-EDTA (for cell cultue) Life technologies, Darmstadt, G 
Tween20  Roth, Karlsruhe, G 
2-mercaptoethanol  Roth, Karlsruhe, G 
3,3',5,5'-Tetramethylbenzidine (TMB)   KPL, Maryland, USA 
 
 
2.2 Buffers and solutions 
 
Phosphate buffered saline (PBS)  13.7 mM NaCl, 8.0 mM Na2HPO4,  
 2.7 mM KCl, 1.5 mM KH2PO4 (pH 7.4) 
 
Tris buffered saline (TBS)                                 20 mM Tris, 137 mM NaCl (pH 7.6) 
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Cell lysis  
 
Lysis buffer   10 mM Tris-HCl pH 7.2, 150 mM NaCl, 
 1% Triton X-100, 1% sodium deoxycholate,  
 EDTA-free protease inhibitor cocktail 
 
 
Cell staining 
 
Fixation solution   PBS plus 2% PFA  
 
Blocking solution  PBS plus 1.5% BSA, 1.5% goat normal serum 
 
Bisbenzimide solution   PBS plus 0.25 µg/ml bisbenzimide 
 
 
ELISA/Western blot 
 
PBS-T   PBS plus 0.05% Tween20  
 
TBS-T  TBS plus 0.1% Tween20  
 
Towbin transfer buffer 25 mM Tris, 192 mM Glycin,  
 20% Methanol (pH 8.3)             
 
 
ADI activity  
 
Reagent 1                                                         25% (v/v) 98% H2SO4, 20% (v/v) 85% H3PO4,  
 0.025% (w/v) FeCl3 
                                                                                         
Reagent 2                                                           0.5% (w/v) diacetyl monoxime, 
                                                                          1.2 mM thiosemicarbazide 
 
Reagent 3                                                          2 parts reagent 1 : 1 part reagent 2 
 
 
Flow cytometry 
 
Wash buffer  PBS plus 1% (v/v) FCS 
 
Fixation buffer  PBS plus 4% (v/v) PFA 
 
 
Gel electrophoresis 
 
TAE electrophoresis buffer                          40 mM Tris, 0.11% (v/v) acetic acid,  
 0.2% (v/v) 0.5 M EDTA 
 
GelGreen
™
 solution                                          150 ml dH2O plus 45 µl GelGreen
™
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Generation of moDC 
 
MACS buffer                                                  PBS plus 0.5% BSA and 2 mM EDTA 
                                                                      sterile filtration 
 
 
PAD activity  
 
Deamination buffer                                  40 mM Tris-HCl (pH 7.5), 5 mM CaCl2,  
 1mM DTT 
 
 
Protein purification 
 
Buffer A 25 mM Hepes, 150 mM NaCl,  
  5 mM imidazole (pH 7.5) 
 
Buffer B  25 mM Hepes, 150 mM NaCl,  
 1 M imidazole (pH 7.5) 
 
 
SDS-PAGE 
 
Coomassie staining solution                            0.25% (v/v) Coomassie Brilliant Blue R-250,  
 45% (v/v) methanol, 10% (v/v) acetic acid 
 
Coomassie destaining solution                        20% (v/v) methanol, 7% (v/v) acetic acid 
 
10% SDS gel consist of:  
 
SDS-PAGE separation gel (10%) 3.3 ml Rotiphorese
®
 Gel 30 (37.5:1),  
 2.5 ml 1.5 M Tris (pH 8.8),  
 0.1 ml 10% SDS, 4 µl TEMED,  
 0.1 ml 10% APS, 4.0 ml dH2O 
 
SDS-PAGE stacking gel (5%) 0.5 ml Rotiphorese
®
 Gel 30 (37.5:1),  
 0.38 ml 1.0 M Tris (pH 6.8),  
 30 µl 10% SDS, 3 µl TEMED,  
 30 µl 10% APS, 2.1 ml dH2O 
 
SDS running buffer                                      25 mM Tris, 192 mM glycin, 0.4% (w/v) SDS           
 
Tris-Hepes-SDS running buffer               100 mM Tris, 100 mM Hepes,  
 0.1% (w/v) SDS       
 
 1 x SDS reducing loading buffer    50 mM Tris-HCl (pH 6.8), 2% SDS,              
                                                                         0.01% bromophenol blue, 10% glycerol,  
 100 mM 2-mercaptoethanol 
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3 x SDS reducing loading buffer 3.5 ml 4 x SDS/Tris-HCl buffer (pH 6.8),  
 1.5 ml glycerol (87%), 175 mM SDS,  
 302 mM DTT 
 
5 x SDS reducing loading buffer                       250 mM Tris-HCl (pH 6.8), 10% SDS,              
                                                                         0.05% bromophenol blue, 50% glycerol,  
 500 mM 2-mercaptoethanol 
 
4 x SDS/Tris-HCl buffer (pH6.8) 5% SDS, 0.5 M Tris-HCl pH 7.4,  
 0.125 M EDTA 
 
 
2.3 Antibodies (for Western blot analysis) 
 
Antibodies used for Western blot analysis are summarized in Tab. 2 and 3. 
 
Table 2: Primary antibodies 
Antigen Source Dilution Type Manufacturer Catalog number 
anti-Histidine-tag mouse 1:2500 
mAb, 
purified 
Linaris, 
Dossenheim, G 
MAK 1396 
(clone AD1.1.10) 
anti-p70 S6 Kinase rabbit 1:1000 
pAb, 
purified 
Cell signaling, 
Danvers, USA 
#9202 
anti-Phospho- 
p70 S6 Kinase 
(Thr389) 
rabbit 1:1000 
pAb, 
purified 
Cell signaling, 
Danvers, USA 
#9205 
anti-E4-BP1 rabbit 1:1000 
pAb, 
purified 
Cell signaling, 
Danvers, USA  
#9452 
anti-Phospho- 
4E-BP1 (Thr70) 
rabbit 1:1000 
pAb, 
purified 
Cell signaling, 
Danvers, USA 
#9455 
anti-β-Actin rabbit 1:1000 
pAb, 
purified 
Cell signaling, 
Danvers, USA 
#4967 
anti- 
G. duodenalis ADI 
llama 1:2500 
pAb, 
antiserum 
Preclinics, 
Potsdam, G 
individual order 
 
 
Table 3: Secondary antibodies  
Antigen Source Dilution Type Manufacturer 
Catalog 
number 
anti-rabbit IgG-HRP goat 1:2000 
pAb, 
purified 
Cell signaling, 
Danvers, USA 
#7074 
anti-mouse IgG-HRP rabbit 1:5000 
pAb, 
purified 
Jackson 
ImmunoResearch, 
West Grove, USA 
315-035-003 
anti-llama IgG-HRP goat 1:10000 
pAb, 
purified 
Bethyl 
Laboratories, 
Montgomery, USA 
A160-100P 
 
Material 
22 
 
2.4 Oligonucleotides 
 
All primers used in this study are summarized in Tab. 4. Primer design, except for 
ENTRY-FW/BW, was based on sequence information from GiardiaDB (www.giardiadb.org), 
carried out with Geneious Pro 5.4.3 (Biomatters Ltd.) and ordered from Eurofins MWG 
(Ebersberg, G).   
 
Table 4: List of primers used in this study 
Name Sequence (5’ – 3’) Application 
gd-3_s AATGACTGACTTCTCCAAGGATAAAGA cloning 
gd-5_as TCCCTCACTTGATATCGACGCAGATGTCA cloning 
gd-11_as CGGCGGGGGCCGGTGCTTTG ADI amplification/ 
sequencing 
gd-12_s GTCCGCAACACGGCTCTCGTTAC sequencing 
gd-15_as CCGAGGCGCTTCCAGAAGAT sequencing 
gd-20_s CTGACAAGCACTTCATTTACTG ADI amplification/ 
sequencing 
gd-6_a TGCGTGACCAGCAGATAACC sequencing 
ENTRY-FW_s GCGAAACGATCCTCGAAGC sequencing 
ENTRY-BW_as CCCCTGATTCTGTGGATAACCG sequencing 
C424A-FW_s GTACGGCTCTCTGCACGCCGCATCTCAGGTTGTT mutagenesis 
C424A-BW_as AACAACCTGAGATGCGGCGTGCAGAGAGCCGTAC mutagenesis 
pASG-IBA35-FW_s GAGTTATTTTACCACTCCCT sequencing 
pASG-IBA35-BW_as CGCAGTAGCGGTAAACG sequencing 
pASG-IBA35-tet-FW_s GGGGGCGGAGCCTATGGAAA sequencing 
pASG-IBA35-tet-BW_as GGTCAAGCTTGCGGGTGGCT sequencing 
 
 
 
2.5 Media 
 
Caco-2 growth medium (MEM20) 80% MEM with Earle’s Salts, 20% FCS, 
 1% glutamine, 1% 100 x NEAA, 
 100 U/ml penicillin/100 µg/ml 
 streptomycin  sterile filtration 
 
DC growth medium (R10FCS)                     RPMI 1640 plus 10% FCS,  
 10 mM Hepes, 100 U/ml penicillin/ 
 100 µg/ml streptomycin,  
 50 µM 2-mercaptoethanol 
  sterile filtration 
 
DC growth medium (-ArgR10FCS)  RMPI 1640 (arginine-free) plus 10% dialyzed  
 FCS, 10 mM Hepes, 100 U/ml penicillin/ 
 100 µg/ml streptomycin,  
 50 µM 2-mercaptoethanol  
  sterile filtration 
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Giardia growth medium    basic medium (18 g/l peptone from casein, 
 9 g/l yeast extract, 56 mM glucose,  
 30 mM NaCl, 1 mM ascorbic acid, 
  6 mM K2HPO4, 4 mM KH2PO4) plus  
 10% (v/v) FCS, 0.05% (w/v) bile from bovine,  
 0.00228% (w/v) ammonium ferric citrate,  
 0.2% (w/v) cysteine, 100 U/ml penicillin/  
 100 µg/ml streptomycin (pH 7.0) 
  sterile filtration 
 
LB agar  LB medium plus 1.5% bacto agar  
  autoclaving 
 
LB medium 10 g/l bacto tryptone, 5 g/l yeast extract,   
 10 g/l NaCl (pH 7.5) 
  autoclaving 
 
SOB medium  20 g/l bacto tryptone, 5 g/l yeast extract, 
 10 ml/l 1 M NaCl, 2.5 ml/l 1 M KCl, 
  autoclaving 
 
SOC medium  SOB medium plus 20 mM glucose 
  steril filtrated 
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2.6 Plasmids 
 
All plasmids that were used in this study are summarized in Tab. 5. 
 
Table 5: List of used plasmids 
E. coli cells transformed with plasmids carrying a kanamycin resistance gene were cultured with 50 µg/ml and 
those carrying an ampicillin resistance gene with 100 µg/ml of the appropriate antibiotic. Ass: assemblage. 
 
Plasmid Characteristics 
pENTRY-IBA10 
cloning site, kanamycin resistance gene, 
size: ~ 1800 bp 
pENTRY-IBA10+ADI (AssA) 
pENTRY-IBA10 plus inserted ADI 
(assemblage A) gene, size: ~ 3550 bp 
pMK-RQ+ADI(AssB) 
kanamycin resistance gene, ColEI ori, synthetic 
(codon optimized) ADI (assemblage B) gene, 
size: ~ 4050 bp 
pMK-RQ+ADI(AssE) 
kanamycin resistance gene, ColEI ori, synthetic 
(codon optimized) ADI (assemblage E) gene, 
size: ~ 4050 bp 
pUC19 
multiple cloning site, LacZ, LacI, ampicillin 
resistance gene, size: ~ 2700 bp 
pASG-IBA35 
f1 origin, ampicillin resistance gene, 
Tet-repressor, ColEI ori, Tet promoter, 
expression cassette with hexahistidine (His6)-tag, 
size: ~ 3200 bp 
pASG-IBA35 (w/o His6-tag) 
pASG-IBA35 without His6-tag, 
size: ~ 3200 bp 
pASG-IBA35+ADI(AssA) 
pASG-IBA35 plus inserted ADI (assemblage A) 
gene, size: ~ 4450 bp 
pASG-IBA35+ADIC424A(AssA) 
pASG-IBA35 plus inserted mutated ADIC424A 
(assemblage A) gene, size: ~ 4450 bp 
pASG-IBA35+ADI(AssB) 
pASG-IBA35 plus inserted ADI (assemblage B) 
gene, size: ~ 4450 bp 
pASG-IBA35+ADI(AssE) 
pASG-IBA35 plus inserted ADI (assemblage E) 
gene, size: ~ 4450 bp 
 
 
 
2.7 Equipment 
 
ApoTome Zeiss, Jena, G 
Atmosphere Generation System  Oxoid, Wesel, G 
(AnaeroJar
™
/AnaeroGen
™
)  
Axioskop2  Zeiss, Jena, G 
ÄktaFPLC system  GE Healthcare, Munich, G 
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Flow cytometer LSR II  BD, Heidelberg, G 
Gel documentation system DIAS II  Serva, Heidelberg, G 
Gel electrophoresis chamber  Bio-Rad, Munich, G 
Helios Gamma Spectrophotometer Thermo Scientific, Karlsruhe, G 
Heracell 150i           Thermo Scientific, Karlsruhe, G 
Heraeus
®
 Multifuge
®
 1S-R  Thermo Scientific, Karlsruhe, G 
High-pressure homogenizer EmulsiFlex  Avestin, Mannheim, G Incubator  
Incubator shaker Innova
®
40 New Brunswick, Edison, USA  
Microplate reader Infinite M200Pro  Tecan, Crailsheim, G 
Nalgene
®
 freezing container Sigma, Steinheim, G 
NanoDrop
®
 ND-1000 Spectrophotometer Thermo Scientific, Karlsruhe, G 
Neubauer counting chamber  Marienfeld, Lauda-Königshofen, G 
Power PAC3000  Bio-Rad, Munich, G 
Rocking platform VWR, Darmstadt, G 
SDS electrophoresis chamber  Bio-Rad, Munich, G 
Semi-Dry electro blotter  Peqlab, Erlangen, G 
Sonifier Cell Disruptor W-350  Brandson ultrasonics, Danbury, USA 
Sorvall RC-5B superspeed centrifuge DuPont Instruments, Newtown, USA 
Tabletop centrifuge himac VWR, Darmstadt, G 
Thermal Cycler Bio-Rad, Munich, G 
Thermomixer compact  Eppendorf, Hamburg, G 
 
 
 
2.8 Expendable materials 
 
HisTrap
™
FF column  GE Healthcare, Munich, G 
Maxisorp 96-well ELISA plate  Nunc, Wiesbaden, G 
Ni-NTA HisSorb Strips  Qiagen, Hilden, G 
Nitrocellulose membrane     Bio-Rad, Munich, G 
PD-10 column  GE Healthcare, Munich, G 
Pore size filter (0.22 µm, 0.45 µm)                              Sartorius, Göttingen, G 
Vivaspin concentrator (5 kDa PES membrane) Sartorius, Göttingen, G 
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2.9 Biologicals 
 
2.9.1 Bacterial strains 
 
All E. coli strains that were used in this study are summarized in Tab. 6. 
 
Table 6: List of used E. coli strains 
E. coli strain Genotype 
Used antibiotic(s) 
for cultivation 
DH5αZ1 
(F-) supE ΔlacU169 ΔargF hsdR17 recA1 endA1 gyrA96 
thi-1 relA1, tetR+ lacIq+ SpecR 
spectinomycin 
(50 µg/ml) 
ER2508 
F- ara-14 leuB6 fhuA2 Δ(argF-lac)U169 lacY1 
lon::miniTn10(TetR) glnV44 galK2 rpsL20(StrR) xyl-5 
mtl-5 Δ(malB) zjc::Tn5(KanR) Δ(mcrC-mrr)HB101 
kanamycin 
(25 µg/ml) 
tetracycline 
(12 µg/ml) 
JWK clpX-1 
BW25113:lacIq rrnB3 ΔlacZ4787 hdsR514 Δ(araBAD)567 
Δ(rhaBAD)568 rph-1 FRT::ΔclpX/Kan::FRT 
kanamycin 
(50 µg/ml) 
XL1-Blue 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ 
proAB lacIqZΔM15 Tn10 (TetR)] 
- 
 
 
 
2.9.2 Eukaryotic cell lines 
 
Caco-2 cells (DSMZ Accession No. ACC 169) were established from the primary colon 
tumor (adenocarcinoma) of a 72-year-old Caucasian man in 1974 (Fogh et al., 1977; Rousset, 
1986). These IEC have a doubling time of ~ 80 h and grow in colonies after splitting. In 
contrast, confluent cells grow as epithelial adherent cells and are differentiated 17-21 days 
post-confluence.    
 
In 1979, G. duodenalis WB strain (ATCC
®
 30957
™
) was isolated from a 30-year-old white 
American man chronically infected since traveling to Afghanistan in 1977 (Smith et al., 
1982). The 1983 established clone of this strain, G. duodenalis WB clone C6 
(ATCC
®
 50803
™
), was used as laboratory strain in this study. Additionally, in the Aebischer 
research group Giardia cysts were isolated from human stool samples, excystated and diluted 
to obtain trophozoite population lines routinely. These parasitic isolates, as well as the 
laboratory strain WB-C6, were genotypically characterized by PCR and subsequent 
sequencing of the triosephosphate isomerase locus according to a published protocol from 
Sulaiman et al. (2003). After alignment with reference sequences filed in GiardiaDB 
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(www.giardiadb.org), trophozoite population lines along with patient and genotype 
information were collected in a G. duodenalis biobank and used for this study (Tab. 7). 
 
Table 7: List of G. duodenalis strains used in this study 
Name 
Assumed 
origin of 
acquired 
infection 
Assem-
blage 
Course of  
disease 
Clinical symptoms 
Therapy-
refractory 
(MTZ) 
WB-C6 Afghanistan AI chronically 
vomiting, abdominal 
cramps, flatulence, 
diarrhea (foul-smelling, 
watery stools), weight 
loss 
yes 
 16-01/E1 Ghana AII chronically 
no (or only weak) 
complaints 
yes 
 11-04/E3 India AII chronically severe complaints yes 
 14-03/F7 
Dominican 
Republic 
AII chronically malabsorption yes 
 115-01/H2 Belize AII 
self-limited 
 arguable 
indeterminable  co-
infection with Clostridium 
difficile 
no 
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3 Methods 
 
3.1 Molecular biological methods 
 
3.1.1 Genomic DNA extraction 
 
Genomic G. duodenalis DNA from each patient isolate or the laboratory strain WB-C6 was 
extracted from approximately 1 x 10
7
 trophozoites that were harvested at 4°C for 5 min at 
900 x g and then washed in PBS. DNA was isolated with the QIAamp DNA stool Mini Kit 
(Qiagen) according to the manufacturer’s manual. Finally, DNA concentration was measured 
with NanoDrop ND-1000 Spectrophotometer. DNA was stored at 4°C. 
 
 
3.1.2 Agarose gel electrophoresis 
 
DNA samples were mixed with 6 x loading dye (Fermentas) and loaded on a 1% agarose gel. 
Separation took place in a horizontal gel electrophoresis chamber at 5-10 V/cm electrode 
distance using TAE electrophoresis buffer. To visualize DNA, the gel was stained after 
electrophoresis in GelGreen
TM
 solution for 15 min. GelGreen
TM
 intercalated as a fluorescent 
nucleic acid dye into DNA and was excited by visible blue light with gel documentation 
system DIAS II. DNA size marker GeneRuler
TM
 1 kb Plus DNA Ladder (Fermentas) was 
used to determine the length of DNA fragments.  
 
 
 
3.1.3 Preparation of chemically competent E. coli bacteria 
 
To prepare chemically competent E. coli bacteria, an overnight pre-culture was diluted 1:50 in 
200 ml LB medium containing the appropriate antibiotics. E. coli bacteria were incubated at 
37°C under agitation at 155 rpm until an OD600 of 0.3-0.4 was reached. Afterwards, the 
culture was centrifuged at 4°C for 10 min at 3000 x g. Supernatant was discarded and pellet 
was resuspended in pre-chilled 8 ml 100 mM CaCl2. After resting on ice for 20 min, culture 
was centrifuged and resuspended again in pre-chilled 8 ml 100 mM CaCl2. After incubation 
overnight at 4°C, 4 ml of pre-chilled 60% glycerol was added, bacteria were aliquoted and 
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stored until usage at -80°C. A transformation efficiency of 0.1-1.0 x 10
8
 cfu/μg pUC19 DNA 
was calculated. 
 
 
3.1.4 Transformation 
 
For transformation, 200 µl chemically competent bacteria were thawed for 30 min on ice. 
Plasmid DNA of 50-100 ng was added and bacteria were rested on ice for further 10 min. 
Bacteria were heat shocked for 90 sec at 42°C and immediately transferred on ice. After 
2 min, 1 ml SOC medium was added and bacteria were incubated for 1 h at 37°C.  To 
concentrate bacterial inoculum, culture was centrifuged for 1 min at 10100 x g and 1 ml 
supernatant was discarded. Bacterial pellet was then resuspended in the remaining volume and 
plated on LB agar that contained the appropriate antibiotics. Agar plates were incubated 
overnight at 37°C. After separation and testing of single clones, bacterial glycerol stocks were 
prepared. 
 
 
3.1.5 Preparation of glycerol stocks 
 
Bacterial glycerol stocks were prepared by addition of 200 µl 80% sterile glycerol to 800 µl 
overnight E. coli culture and were frozen immediately in liquid nitrogen. Until usage bacteria 
were stored at -80°C. 
 
 
3.1.6 Isolation of plasmid DNA 
 
Three ml LB medium supplemented with appropriate antibiotics were inoculated with a single 
colony of transformed E. coli bacteria and incubated at 37°C overnight. Then, plasmid DNA 
isolation was carried out using Zyppy™ Plasmid Miniprep Kit according to manufacturer's 
information (ZymoResearch, Freiburg, G). Concentration of plasmid DNA was measured 
with NanoDrop ND-1000 Spectrophotometer and plasmid DNA was stored at 4°C. 
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3.1.7 Restriction digest and ligation 
 
After isolation, plasmid DNA was controlled by restriction digest. Plasmid DNA was 
incubated for 15 min at 37°C with the restriction enzyme Sac (FastDigest®) according to 
manufacturer’s manual (Fermentas). DNA fragments were visualized via agarose gel 
electrophoresis.  
For preparation of the control plasmid pASG-IBA35 (w/o His6-tag), the vector 
pASG-IBA35+ADI was digested with the restriction enzymes Xba and Hind  
(FastDigest
®
) according to manufacturer’s instructions (Fermantas). The complete reaction 
mixture was loaded on an agarose gel and DNA of the linearized vector was extracted. 
Resultant overhangs were filled with Klenow fragment according to manufacturer’s manual 
(Fermantas) and DNA was extracted from gel after agarose gel electrophoresis. Blunt-end 
linearized vector was then ligated with T4 DNA ligase as described by the manufacturer 
(Fermentas). Ligation mixture was directly used for transformation into E. coli. Successful 
preparation of the control vector pASG-IBA35 (w/o His6-tag) was verified by Spe 
(FastDigest
®
) after transformation following the manufacturer’s instructions (Fermentas). 
 
 
3.1.8 DNA extraction from gel 
 
After amplification of ADI from genomic G. duodenalis DNA, entire PCR reaction mixture 
was loaded on an agarose gel. The desired PCR fragment was isolated from the gel using a 
clean scalpel. Same procedure was also performed in case of digested pASG-IBA35+ADI 
plasmid. DNA was extracted with the QIAquick
®
 Gel Extraction Kit according to 
manufacturer’s information (Qiagen). Purified DNA was analyzed on an agarose gel and 
stored at until use 4°C.      
 
 
3.1.9 Purification of PCR products  
 
To remove primers, excessive dNTP’s and polymerase after PCR, amplified DNA was 
purified using the DNA Clean and Concentratot
TM
-25 Kit (ZymoResearch). Until sequencing 
purified PCR fragments were stored at 4°C.  
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3.1.10 Cloning of G. duodenalis ADI with StarGate
® 
 
The 1.8-kb ADI (assemblage A) PCR fragment obtained from the amplification of genomic 
G. duodenalis WB-C6 DNA was purified by gel extraction and cloned into the entry vector 
pENTRY-IBA10 to generate the donor vector pENTRY-IBA10+ADI (AssA). The donor 
vector was mixed with the acceptor vector pASG-IBA35 to generate the destination vector 
pASG-IBA35+ADI(AssA) for expression of the recombinant protein with an N-terminal 
His6-tag. This cloning procedure was performed using the StarGate
®
 system in accordance to 
the manufacturer’s information (IBA).  
For the expression of recombinant ADI of assemblage B and E, both genes were synthesized 
(codon optimized,  flanked by BsmBI restriction sites,  start codon replaced to AATG, stop 
codon replaced to GGGA) by GeneArt
®
 (Invitrogen, Darmstadt, G) in a plasmid lacking a 
BsmBI cleavage site and carrying a kanamycin resistance gene. In the subsequent cloning 
procedure with the StarGate
®
 system, these delivered plasmids were used as donor vector 
equivalents. 
 
 
3.1.11 Site-directed mutagenesis 
 
To obtain a catalytically inactive mutant form of ADI (ADIC424A), cysteine was replaced with 
alanine at amino acid sequence position 424. Site-direct mutagenesis was carried out with the 
three-step procedure of the QuikChange
®
 II Site-Directed mutagenesis kit according the 
manufacturer’s instructions (Agilent, Böblingen, G). First, point-mutation was inserted by 
PCR using the mutagenic primers C424A-FW/C424A-BW and the expression vector 
pASG-IBA35+ADI as template. Second, parental methylated and hemimethylated DNA was 
digested to select for mutation-containing synthesized DNA. The principle behind is that 
template DNA purified from dam
+
 E. coli strain is methylated and thus will be a substrate for 
DpnI, a restriction enzyme that cleaves only when its recognition site is methylated. In 
contrast, the newly synthesized DNA is unmethylated and therefore will be not digested. 
Thus, in a third step, the mutated vector could be transformed. After transformation, plasmid 
DNA was prepared and gene of interest (GOI) sequence checked by DNA sequencing to 
verify nucleotide exchange.  
 
 
Methods 
32 
 
3.1.12 PCR for amplification of ADI from genomic G. duodenalis DNA 
 
For expression of recombinant ADI of assemblage A, its coding sequence was amplified from 
genomic DNA of G. duodenalis strain WB-C6 by PCR. This was carried out with the 
proofreading Pfu DNA Polymerase (Tab. 8) according to manufacturer’s information 
(Promega, Mannheim, G) under conditions that are summarized in Tab. 9. 
 
Table 8: Reaction mixture for amplification of G. duodenalis WB-C6 ADI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9: Thermocycler conditions for amplification of G. duodenalis WB-C6 ADI 
 
 1x           denaturation                2 min    95°C                                     
  denaturation                   30 sec  95°C                   
 35x primer-annealing            30 sec  60°C                       
  elongation                        3 min 40 sec  72°C  
 1x polishing                           5 min  72°C 
 storage    4°C     
 
 
 
To identify sequence variants, ADI was amplified from genomic DNA of G. duodenalis 
patient isolates or the laboratory strain WB-C6 with MangoTaq
TM
 DNA Polymerase (Tab. 10) 
as described by the manufacturer (Bioline, Luckenwalde, G). The PCR conditions are shown 
in Tab. 11. 
 
 
 
 
 
 
 
Reaction mixture (50 µl) 1x 
genomic DNA (20 ng/µl) 10 µl 
Pfu DNA Polymerase  
10x Reaction Buffer with MgSO4 
5 µl 
40 mM dNTP 1 µl 
10 mM Primer-gd3 1 µl 
10 mM Primer-gd5 1 µl 
Pfu DNA Polymerase (2–3 U/μl) 0.5 µl 
dH2O 31.5 µl 
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Table 10: Reaction mixture for amplification of genomic G. duodenalis ADI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11: Thermocycler conditions for amplification of genomic G. duodenalis ADI 
 
 1x           denaturation                3 min   96°C                                     
  denaturation                   30 sec 96°C                   
 35x primer-annealing            30 sec 58°C                       
  elongation                        2 min 30 sec  72°C  
 1x polishing                           7 min 72°C 
 storage    4°C     
 
 
 
3.1.13 DNA sequencing 
 
Purified PCR fragments (10-20 ng/reaction) or plasmid DNA (150-300 ng/reaction) were used 
as templates for DNA sequencing (Tab. 12) that was carried out with the BigDye® 
Terminator v 3.1 Cycle Sequencing Kit as recommended by the manufacturer (Life 
technologies). Primers ENTRY-FW, ENTRY-BW and gd-6 were used to prove whether 
cloned (mutagenized) ADI sequence was correctly inserted into the vector pENTRY-IBA10. 
Furthermore, to evaluate the insertion into the vector pASG-IBA35, primer pASG-IBA35-
FW, pASG-IBA35-BW and gd-6 were used. For sequencing of genomic ADI from different 
G. duodenalis patient isolates and the laboratory strain WB-C6 the primer gd-11, gd-12, 
gd-15 and gd-20 were applied. Amplification was carried out as described in Tab. 13. 
Remaining working steps were performed by the internal sequencing service of the RKI. 
Sequence files of each primer were finally analyzed with SeqMan Pro
TM
 software 
(DNASTAR
®
, Inc.) to obtain contig-sequences. Those were aligned using ClustalW (EMBL-
EBI). For translation of nucleic acid into peptide sequences EMBOSS Transeq (EMBL-EBI) 
was used. 
Reaction mixture (25 µl) 1x 
DNA sample (20-50 ng/µl) 1 µl 
5 x MangoTaq
TM
 reaction buffer 5 µl 
40 mM dNTP 0.5 µl 
50 mM MgCl2 0.75 µl 
10 mM Primer-gd11 0.5 µl 
10 mM Primer-gd20 0.5 µl 
MangoTaq
TM
 DNA Polymerase (5 U/µl) 0.25 µl 
dH2O 16.5 µl 
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Table 12: Reaction mixture for DNA sequencing 
 
 
 
 
 
 
 
 
 
 
Table 13: Thermocycler conditions for DNA sequencing 
 
 1x           denaturation                2 min    96°C                                     
  denaturation                   10 sec  96°C                   
 25x primer-annealing            5 sec   60°C                       
  elongation                        4 min                       60°C  
 storage    4°C     
 
 
 
3.2 Biochemical methods 
 
3.2.1 Protein characterization 
3.2.1.1 Determination of protein concentration 
The protein concentration was determined with the Pierce
®
 BCA Protein Assay Kit according 
to the manufacturer's manual (Thermo Scientific). BSA standard, that was included in the kit, 
was diluted for a linear working range in PBS. Absorbance was measured at 562 nm with the 
microplate reader Infinite M200Pro. 
To investigate the ADI expression of various transformed E. coli strains, similar protein 
amounts in SDS-PAGE and Western blot analysis were compared. Therefore, the harvested 
bacterial pellets were resuspended in 3 x SDS loading buffer after thawing and were then 
diluted with PBS to a final SDS concentration less than 5%. To have an equivalent standard, 
to BSA samples diluted in PBS 3 x SDS loading buffer was added in corresponding amounts.   
  
 
 
 
Reaction mixture (10 µl) 1x 
DNA sample 1.5 µl 
5 x buffer 1.5 µl 
10 mM Primer 0.5 µl 
Sequencing mix (BigDye 3.1) 1.0 µl 
dH2O 5.5 µl 
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3.2.1.2 Enzymatic activity assay 
The enzymatic activity of recombinant ADI and ADIC424A was measured by colorimetric 
determination of citrulline formation as described previously (Knodler et al., 1995) and was 
found to be stable for the duration of the study. 
The verification of citrulline is based on a two-step reaction that runs under acidic conditions 
(Fig. 3). In a condensation reaction of citrulline with diacetyl monoxime a glycolurile derivate 
is formed. In presence of heat, concentrated acid, Fe
3+
 and oxygen, this derivate converts into 
a dye that can be measured photometrically (Lorentz and Koch, 1971). In the first reaction 
step, hydroxylamine is formed as side product. This reducing agent disturbs the color 
development and therefore is necessary to be removed by the addition of thiosemicarbazide 
(Knipp and Vasák, 2000). The reaction conditions are achieved by usage of freshly prepared 
reagent 3, that is a mixture of reagent 1 (including acids and Fe
3+
) and reagent 2 (including 
diacetyl monoxime and thiosemicarbazide).  
 
 
       
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Figure 3: Chemical reaction for the verification of citrulline 
 
 
To determine the enzymatic activity, 10 µl of (thawed) purified recombinant enzyme 
(0.5-2 µg/ml) was added to 30 µl 40 mM Hepes buffer (pH 7.0) and 10 µl 100 mM arginine 
(prepared in dH2O). As negative control 10 µl recombinant enzyme was replaced by PBS. The 
reaction mixture was incubated for 10 min at 37°C. Deimination of arginine was stopped by 
addition of 10 µl 6% trichloroactetic acid. To determine the enzyme activity, citrulline 
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concentration was measured. Therefore, 200 µl reagent 3 was added and the sample was 
heated to 96°C for 6 min. Finally, the OD at 540 nm was measured in a 96-well microtiter 
plate. To quantify the formed citrulline, a standard curve with citrulline ranging from 
0-625 µM was prepared in parallel. To determine formed citrulline after treatment of moDC 
with recombinant ADI, 10 µl or 20 µl of cell culture supernatants were refilled with dH2O up 
to 50 µl. Ten to twenty µl of DC growth medium was used as negative control. Finally, 200 µl 
of reagent 3 were added and it was proceeded as above described.  
 
 
3.2.1.3 Enzyme kinetics of G. duodenalis ADI 
As a characteristic parameter to describe an enzyme kinetic, the Km value of recombinant and 
native ADI was determined. Therefore, lysates as well as final purified enzymes from the 
DH5αZ1 strain expressing the recombinant ADIs (assemblage A, B and E) were used. For 
preparation of E. coli lysates, 45 ml bacterial cultures were grown to an OD600 between 
2.4-3.0 without induction and pellets were harvested at 4°C with 12000 x g. Bacterial pellets 
were washed in PBS and stored at -80°C. Thawed pellets were resuspended in 10 ml ice-cold 
PBS and disrupted using a French Press. After centrifugation (15000 x g, 30 min, 4°C), 
substrate affinity of ADI for arginine was determined in the supernatants. 
To determine the Km value of native ADI from G. duodenalis trophozoites, lysates were 
prepared. Three cultivation flasks of confluent trophozoites per strain were washed with 
ice-cold PBS and placed for 30 min on ice. Cultures were harvested, combined and 
centrifuged (900 x g, 5 min, 4°C). After additional washing with PBS, cell pellet was 
resuspended in 500 µl PBS, trophozoites were counted in a Neubauer counting chamber and 
frozen at -70°C. Subsequently, frozen trophozoites were thawed, exposed to a second 
freeze/thaw-cycle and finally disrupted by ultrasound (duty cycle 60%, output 6, 4°C) in six 
30 sec periods with 30 sec resting in between. Cell debris was removed by centrifugation for 
20 min at 12000 x g at 4°C. Supernatant was collected and 10 µl lysate was directly [or in 
appropriate dilution with 40 mM Hepes buffer (pH 7.0)] used for the enzyme activity assay. 
To determine the Km value the substrate concentration was varied. Ten µl of different arginine 
concentrations [diluting 100 mM arginine stock solution with 40 mM Hepes buffer (pH 7.0)] 
were applied to obtain final concentrations ranging from 0-15 mM in the assay. As negative 
control 10 µl lysate was replaced by 40 mM Hepes buffer (pH 7.0) for each arginine 
concentration. To calculate the correct turnover, the initial citrulline concentration in the 
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lysates was detect. Therefore, arginine was replaced by 40 mM Hepes buffer (pH 7.0) in the 
reaction mixture. The computation of the Km value was carried out with GraphPAD Prism5.01 
(GraphPAD Software, Inc.). For determination of the specific ADI activity expressed as units 
(U) per trophozoites in G. duodenalis lysates, it was proceeded as described by using only 
20 mM arginine as substrate.  
 
 
3.2.2 SDS gel electrophoresis  
 
For SDS-PAGE (Laemmli , 1970) 5 x SDS reducing loading buffer was mixed with samples 
and heated at 95°C for 5-10 min to completely disrupt secondary and tertiary structures and to 
inactivate potential proteases. To investigate the protein expression after induction of various 
transformed E. coli DH5αZ1 strains, bacterial pellet was directly resuspended in 
3 x SDS reducing loading buffer and was heated at 95°C for 5-10 min. For determination of 
the protein concentration within these samples, 3 x SDS reducing loading buffer was prepared 
without bromophenol blue.  
Samples were then loaded on 10% SDS gels or commercial 4-20% Precise
™
 protein gels 
(Thermo Scientific) and SDS gel electrophoresis was performed in a vertical electrophoresis 
chamber according to manufacturer's instructions (Bio-Rad). SDS-PAGE was carried out in 
SDS running buffer at 10 mA for stacking and at 25 mA for separation. Commercial gels were 
run in Tris-Hepes-SDS running buffer at 100 mA. As molecular weight standard 
PageRuler
™
 Prestained Protein Ladder (Thermo Scientific) was used. Gels were either used 
for Western blot analysis or for Coomassie staining (Sambrook et al., 1989). Proteins were 
visualized by staining of gels with Coomassie staining solution for 2-4 h. Destaining was 
performed overnight at RT under agitation.  
 
 
3.2.3 Western blot analysis 
 
After separation by SDS-PAGE proteins were transferred to nitrocellulose membranes 
(Towbin et al., 1992). Therefore, gels were equilibrated for 15 min and nitrocellulose 
membranes (pore size: 0.45 µM) for 5 min in Towbin transfer buffer. Proteins were 
transferred onto the membrane at 1.2 mA/cm
2
 membrane by constant current regulated by 
Power PAC3000 for 45 min in a Semi-Dry electro blotter. After blotting, the membrane was 
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washed twice in PBS and incubated for 1 h at RT or overnight at 4°C in blocking solution 
(PBS plus 5% milk powder) to saturate nonspecific protein binding sites. The membrane was 
incubated with specific primary antibody (2.3), diluted to working concentrations in blocking 
solution, for 2 h at RT or overnight at 4°C. The membrane was washed thrice for 10 min in 
PBS-T. Bound antibodies were detected with appropriate enzyme-conjugated second antibody 
diluted to working concentrations in blocking solution. The membrane was incubated for 2 h 
at RT and was then washed three times for 10 min in PBS-T. To detect (phosphorylated) 
proteins involved in the mammalian target of rapamycin (mTOR)-signaling pathway, a total 
of 50 µg protein was separated by SDS-PAGE and Western blot analysis were performed as 
described except that membranes were blocked with 5% milk powder-0.1% Tween20-TBS, 
washed with TBS-T and antibodies were diluted in 5% BSA-0.1% Tween20-TBS. TBS was 
preferred to use because anti-phosphate antibodies can interfere with the phosphate groups in 
PBS. Protein detection was carried out either with the BM Chemiluminescence Western blot 
Kit (Roche) or ECL
TM
 Plus Western Blotting Detection reagent (GE Healthcare). In presence 
of hydrogen peroxide (H2O2) the horseradish peroxidase-labeled secondary antibody catalyzes 
the oxidation of luminol (BM kit) or Lumigen PS-3 Acridan (ECL
TM
 Plus kit). As a result, an 
activated intermediate reaction product is formed which decays to the ground state by 
emitting light. Thereby, oxidation of the Lumigen substrate produces a more intense light 
emission of longer duration. Both chemiluminescence signals were visualized on 
autoradiography films (Kodak, Stuttgart, G; GE Healthcare). Quantification of Western blot 
signals was performed with ImageJ 1.42q software (NIH, USA).  
 
 
3.2.4 Protein expression 
 
To verify ADI expression, pre-cultures of various transformed E. coli strains were used as 
inoculum for 25 ml LB medium with the appropriate antibiotics. At an OD600 between 
1.4-1.6, bacteria were induced (for 20 min) or not with 200 ng/ml anhydrotetracycline (AHT) 
and further incubated. One ml bacterial culture was collected and centrifuged for 5 min at 
12000 x g. Pellet was stored at -80°C.  
E. coli DH5αZ1 strains transformed with the expression vectors pASG-IBA35+ADI(AssA), 
pASG-IBA35+ADIC424A(AssA), pASG-IBA35+ADI(AssB) or pASG-IBA35+ADI(AssE) 
were used as inoculum for 5 ml LB liquid cultures supplemented with 100 µg/ml ampicillin 
and 50 µg/ml spectinomycin. After cultivation overnight at 37°C and 180 rpm, 4 ml pre-
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culture were used to inoculate 4 l LB medium supplemented with the same antibiotics. 
Bacteria were grown at 37°C, 180 rpm until an OD600 of 1.5-1.8 was reached. For purification 
of ADI of assemblage B and E, bacteria were induced with 200 ng/ml AHT. Bacterial cells 
were harvested by centrifugation (8200 x g, 10 min, 4°C) and then washed twice in ice-cold 
PBS. Until protein purification, the pellets were stored at -80°C. 
 
 
3.2.5 Purification of recombinant proteins 
 
To purify mutated or wild-type enzyme, frozen pellets were thawed and each was 
resuspended in 25 ml of buffer A plus a half tablet complete EDTA-free protease inhibitor 
cocktail. Bacterial cells were disrupted with a high-pressure homogenizer. After 
centrifugation (15000 x g, 30 min, 4°C), the supernatants were passed through a 
0.45-µm-pore-size filter and loaded onto a HisTrap
TM
FF column pre-equilibrated with 
buffer A on an ÄktaFPLC system. Purification was carried out in two steps: first, unbound 
proteins were washed off with 7% buffer B (equal to ~ 70 mM imidazole), second, proteins 
were eluted in 20% buffer B (equal to ~ 200 mM imidazole). After affinity chromatography 
imidazole was removed by desalting with a PD-10 column, and residual LPS was removed 
with an EndoTrap® kit according to the manufacturer’s manuals (Hyglos, Bernried am 
Starnberger See, G). Recombinant proteins in PBS were concentrated with a Vivaspin 
concentrator (5-kDa PES membrane). The purified enzymes were stored in aliquots at -70°C. 
 
 
3.3 Cell biological methods 
 
3.3.1 Cultivation of parasites 
 
G. duodenalis strain WB-C6 as well as the different patient isolate strain trophozoites were 
propagated in Giardia growth medium (modified TYI-S-33 medium; Keister, 1983) at 37°C 
under anaerobic conditions in flat-sided culture tubes. Twice a week, confluent grown 
cultures were placed on ice for 30 min for detachment of trophozoites and split 1:100 or 
1:1000 with fresh Giardia growth medium.   
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3.3.2 Cryopreservation of parasites 
 
Giardia culture with 0.5-1.0 x 10
7
 trophozoites was centrifuged (900 x g, 4°C, 5 min), 
supernatant discarded and pellet resuspended in 1 ml Giardia growth medium supplemented 
with 10% DMSO. Trophozoites were transferred into a cryo tube that was slowly frozen 
within a freezing container to -70°C. For long term storage cryo tubes were placed in liquid 
nitrogen. Frozen aliquots were thawed and transferred into 10 ml pre-warmed Giardia growth 
medium. After centrifugation (900 x g, 5 min, 4°C), pellet was resuspended in 10 ml Giardia 
growth medium and transferred into a flat-sided culture tube. 
 
 
3.3.3 Cultivation of eukaryotic cell line 
 
Caco-2 cells were cultivated under 5% CO2 at 37°C in T-25 (25 cm
2
) culture flask until a 
confluence of 50-80% was reached. For subcultivation, cell layer was rinsed with PBS and 
incubated with 2 ml 0.05% trypsin-EDTA solution twice a week. After detachment 6 ml 
Caco-2 growth medium (MEM20) was added and cells were split 1:6 with 6 ml fresh Caco-2 
growth medium (MEM20). For cell culture experiments, 100-300 µl of the Caco-2 cell 
suspension was seeded into 12-well tissue culture plates containing 1.5 ml Caco-2 growth 
medium (MEM20) to obtain a confluent cell layer with 8 x 10
5
 cells/well within 3-5 days. The 
cells Caco-2 growth medium (MEM20) m was renewed once a week. For cell staining 
12-well tissue culture plates were additionally equipped with cover glasses. 
 
 
3.3.4 Cryopreservation of Caco-2 
 
For long term storage approximately 2.0 x 10
6
 Caco-2 cells were harvested, centrifuged 
(900 x g, 10 min, RT) and resuspended in 1 ml freezing medium (70% Caco-2 growth 
medium (MEM20), 20% FCS, 10% DMSO). Cell suspension was then transferred into a cryo 
tube that was slowly frozen within a freezing container to -70°C. For long term storage cryo 
tubes were placed in liquid nitrogen. 
Cells were thawed at 37°C and transferred into 10 ml Caco-2 growth medium (MEM20). Cell 
were centrifuged (900 x g, 10 min, RT), supernatant discarded and pellet used as inoculum for 
6 ml Caco-2 growth medium (MEM20) in a T-25 (25 cm
2
) flask.  
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3.3.5 Generation of human moDC 
 
The first step in the generation of human moDC was the isolation of peripheral blood 
mononuclear cells (PBMC) from buffy coats of healthy volunteers (German Red Cross, 
Berlin, G) by density gradient centrifugation. Therefore, two 50 ml-falcon tubes containing 
10 ml Ficoll were overlaid with the entire buffy coat (each with 35 ml) and were centrifuged 
(20 min, 830 x g, RT, without bracket). The resulting interphases were collected separately, 
diluted in a ratio 1:4 in PBS and centrifuged at 4°C for 10 min at 350 x g. The supernatant 
was discarded and the washing step repeated twice. Both pellets were resuspended, each in 
20 ml MACS buffer, combined and PBMC were counted. Afterwards, cells were centrifuged 
and washed once in MACS buffer. Monocytes were enriched by magnetic-activated cell 
sorting (MACS) with CD14 MicroBeads according to the manufacturer’s manual (Miltenyi 
Biotec, Bergisch Gladbach, G). After separation CD14-positive cells were collected in DC 
growth medium (R10FCS), centrifuged (350 x g, 10 min, 4°C) and again washed in the same 
medium. CD14-positive cells were resuspended in 3-4 ml DC growth medium (R10FCS) and 
counted. To quantify enrichment, an aliquot of cells was taken and analyzed in flow 
cytometry. To generate moDC, 3.0 x 10
6 
monocytes/well were seeded into 6-well tissue 
culture plates. Wells contained 3 ml DC growth medium (R10FCS) supplemented with 
1000 U/ml human rGM-CSF and 10 ng/ml human rIL-4. After 6 days, immature DC were 
harvested, centrifuged (350 x g, 10 min, 4°C) and washed depending on the experiment either 
once in DC growth medium (R10FCS) or twice in arg-free RPMI. Afterwards, cell pellet was 
resuspended in 3 ml DC growth medium with (R10FCS) or without arginine (-ArgR10FCS) 
and moDC were counted. Cell population was characterized by analyzing an aliquot by flow 
cytometry.  
 
 
3.3.6 Treatment of human moDC  
 
Immature DC were seeded into a 12-well tissue culture plate at 5 x 10
5
/ml and cultured at 
37°C either in DC growth medium (R10FCS) or in arginine-free DC growth medium 
(-ArgR10FCS) supplemented or not, alone or combined with 2 mM or 0.2 mM arginine, 
citrulline, ammonium chloride, urea or ornithine. Cells were exposed or not to different 
concentrations of recombinant ADI or ADIC424A, and 1 µg LPS/ml or 10 ng LPS/ml was 
added at the same time to trigger DC maturation. Cell culture supernatants were collected 
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after 24 h. An aliquot for detection of formed citrulline was taken and the remaining 
supernatant was frozen at -70°C until cytokine determination. DC were harvested for flow 
cytometry analysis. 
To investigate the impact of arginine turnover by ADI on the mTOR signaling pathway, 
1 x 10
6
 immature DC/well were seeded into a 12-well tissue culture plate in 1 ml arginine-free 
DC growth medium (-ArgR10FCS) containing 1000 U/ml human rGM-CSF and 10 ng/ml 
human rIL-4 and further supplemented or not with 2 mM arginine, citrulline and/or 
ammonium chloride. After 30 min of resting, cells were treated with 2 µM rapamycin, 
recombinant ADI, or ADIC424A and further cultured at 37°C for 90 min. The immature cells 
were then exposed to 1 µg/ml LPS. For flow cytometry analysis, cells were harvested after 
24 h. In parallel, for citrulline detection and Western blot analysis, cells were harvested after 
30 min by centrifugation (300 x g, 10 min, 4°C). Supernatants were collected and cell pellets 
were washed twice in ice-cold PBS before resuspension in 80 µl lysis buffer. After incubation 
for 30 min on ice, cell debris was removed by centrifugation (5 min, 14000 x g, 4°C) and 
lysates were stored at -70°C.  For Western blot analysis, lysates were thawed and protein 
concentration was determined.  
 
 
3.3.7 Detection of ADI release 
 
To verify that ADI is released by Giardia trophozoites after contact with Caco-2 cells, 
different patient isolates as well as the laboratory strain WB-C6 were incubated with these 
cells. Parasites were washed with PBS, incubated on ice for 30 min and harvested by 
centrifugation (900 x g, 5 min, 4°C). After a further washing step in PBS trophozoites were 
resuspended in Caco-2 growth medium without FCS and counted. Differentiated Caco-2 cells 
that were washed with PBS were treated with the parasites (MOI of 3). After 45 min cell-
culture supernatants were harvested, centrifuged (10 min, 930 x g, 4°C) and 450 µl cell-free 
supernatants were mixed with 2 volumes 100% acetone. After incubation overnight at -20°C 
the precipitated proteins were harvested by centrifugation (12000 x g, 20 min, 4°C). 
Supernatant was discarded and pellet dried. Proteins were resuspended in 20 µl 
1 x SDS reducing loading buffer, heated for 5 min at 96°C and separated by SDS-PAGE for 
Western blot analysis.  
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3.3.8 Eukaryotic cell staining 
 
To investigate cell morphology, differentiated (17-21 days post-confluence) Caco-2 cells 
grown on cover glasses were fixed with fixation solution for 30 min at 37°C. Fixation solution 
was exchanged with PBS. After incubation for 1 h at RT, PBS was replaced by fresh PBS and 
cells were washed thrice for 5 min. Differentiated Caco-2 cells were then stained with the 
DiffQuik
®
 staining set (Medion Diagnostics, Gräfelfing, G). In a first step cells were again 
fixed for 30 sec on cover slips by incubation in a solution containing methanol. Afterwards, 
cells were colorized for 20 sec in a solution containing eosin, for 15 sec in a solution 
containing methylene blue and were then rinsed in PBS. Stained cover slips were fixed on 
microscope slides with Entellan
®
 and analyzed under the microscope. 
To verify formation of tight junction between Caco-2 cells, cover slips were prepared for 
staining procedure as described above. After the last washing step with PBS, cells were 
blocked for 1 h in blocking solution. Blocking solution was then removed and 2.5 µg/ml 
polyclonal rabbit anti-ZO-1 antibody (Life technologies) (diluted 1:100 in blocking solution) 
was added. After 1 h, cells were washed thrice with PBS for 5 min and 6.5 µg/ml goat anti-
rabbit-Alexa Fluor
®
488 (Life technologies) secondary antibody (diluted 1:300 in blocking 
solution) was added for 30 min. After three washing steps with PBS for 5 min cells were 
further stained with bisbenzimide, a fluorescent stain for DNA. Therefore, bisbenzimide 
solution was added for 15 min and was then removed by three washing steps in PBS. Stained 
cover slips were fixed on microscope slides with Mowiol 4-88 and analyzed under the 
fluorescence microscope. 
 
 
3.4 Immunological methods 
 
3.4.1 Flow cytometry  
  
In flow cytometry, cells in a fluid pass a laser beam within a flow cytometer where light 
scattering and fluorescent light can be measured. The principle of the technique is based on 
the nature of cells to scatter light differently. Thereby, the scattering of light correlates with 
size and complexity of the cell. These properties are quantified due to two parameters: the 
side scatter (SSC) which serves as an indicator for the granularity and the complexity of a cell 
(e.g. size and structure of the nucleus, amount of vesicles) and the forward scatter (FSC) 
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which is proportional to the volume of the cell. Fluorescent signals are only detected on cells 
that were stained before with fluorescent-labeled antibodies raised against special surface 
proteins. Due to these both parameters, the fluorescence signal and the light scattering, special 
cell types of a cell population can be distinguished.  
To confirm the isolation and enrichment of CD14-positive cells, the generation of moDC and 
the change in cell surface molecules of treated moDC, flow cytometry was performed. After 
MACS, approximately 150000 CD14-positive cells/well were seeded in a 96-well plate. As 
negative control, part of the cells remained unstained to determine auto-fluorescence, others 
were stained with mouse mAb anti-human CD3, CD14 or CD20 as well as the respective iso-
type (IgG1) control for 45 min on ice or overnight at 4°C according to the manufacturer’s 
information (Immunotools). Cells were then washed twice with 150 µl wash buffer by 
centrifugation (670 x g, 2 min, 4°C). Pellets were resuspended in 50 µl wash buffer and cells 
were stained, except the negative control, with polyclonal goat anti-mouse FITC-conjugated 
secondary antibody (Immunotools). After an incubation time of 30 min on ice in the dark, the 
washing procedure was repeated as described above. Subsequently, cell pellets were 
resuspended in 100 µl wash buffer and the same volume of fixation buffer was added. The 
samples were transferred into tubes and data were acquired on an LSR II flow cytometer and 
analyzed by FlowJo software (Tree Star, Inc.). Dead cells were excluded by gating according 
to FSC/SSC characteristics. 
To measure cell surface markers on moDC directly after their generation or after their 
treatment, the same staining procedure was followed except that the following mouse 
conjugated mAb were used: anti-human FITC-CD14 (Immunotools), PerCP-CD86 (Abcam), 
PE-HLA-DR (Immunotools), AlexaFluor488-CD83 (Biolegend, San Diego, USA), 
Dyomics647-CD25 (Immunotools) or iso-type control Biotin-IgG1(Immunotools) with the 
relevant streptavidin-conjugates PE, PERCP, FITC (eBioscience) and Alexa488 (Life 
technologies).  
 
 
3.4.2 ELISA for cytokine detection 
 
The enzyme-linked immunosorbent assay (ELISA) is an immunoassay used to determine 
concentrations of biomolecules (e.g. peptides, cytokines and hormones) in liquids. The 
principle is based on an antibody-antigen reaction that allows quantification. The substrate 
conversion by an enzyme-coupled marker causes a measurable signal. Thereby, intensity of 
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the signal is direct proportional to the amount of investigated biomolecule within the liquid 
(Engvall and Perlmann, 1971). 
To determine cytokine concentrations in cell-culture supernatants, Sandwich-ELISA was 
performed. Therefore, frozen samples from treatment of moDC were thawed and used for 
human TNF-α, IL-10, IL-12p70 (eBioscience), IL-23 (U-CyTech, Utrecht, NL) or 
IL-12p40 ELISA (Biolegend) following manufacturer’s protocols. First, the coating antibody 
was immobilized on the solid material of a Maxisorp 96-well ELISA plate through 
hydrophobic interactions. After washing with PBS-T, free protein binding sites were blocked 
to avoid unspecific binding of enzyme-linked antibodies or antigen molecules. Further 
washing steps followed. Supernatants for cytokine content determination from cell culture 
experiments as well as the respective cytokine standards, included in the ELISA kit, were 
added. If specific cytokines were present, they were bound by the coating antibody. Then, a 
biotin-conjugated detection antibody was added which had also a binding site different from 
the coating antibody for the specific cytokine to form an antibody-antigen-antibody complex. 
After further washing steps, the complex formation was detected by addition of a horseradish 
peroxidase being linked to (strept)avidin which bound the conjugated biotin of the detection 
antibody. Subsequently, TMB, a chromogenic substrate that yields a blue color when oxidized 
with H2O2 to its radical form by horseradish peroxidase (HRP), was added. The enzyme was 
denatured and inactivated by addition of 100 µl 2 M H2SO4 to stop substrate conversion and 
color development. Additionally, due to protonation of the radical, TMB turned yellow and 
was read photometrically at 450 nm in a plate reader.  
 
 
3.4.3 Indirect ELISA for detection of PAD activity  
 
Ni-NTA HisSorb Strips coated with Ni-NTA moieties enabled screening of His6-tagged 
biomolecules. Here, 2.3 µmol H6-CRGKA (VSP-tail) (according to Touz et al., 2008) was 
immobilized for 2 h at RT in 200 µl PBS-1% BSA under agitation. Afterwards, strips were 
washed thrice with PBS-T and finally twice with PBS. To each well 200 µl deamination 
buffer was added. Wells were treated with 200 mU (15 µg) recombinant ADI or similar 
amounts of recombinant ADIC424A, 3 mU ADI of G. duodenalis lysate, as negative 
control PBS and as positive control 25 mU human PAD (MQR, Nijmegen, NL) were added. 
To verify PAD activity strips were incubated for 16 h at 50°C. Afterwards, wells were washed 
four times with PBS-T and 200 µl first antibody (diluted 1:1000 in PBS-1% BSA), a mouse 
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anti-deiminated arginine antibody included in the Antibody Based Assay for PAD activity 
(ABAP) kit (MQR), was added. Strips were incubated at RT for 2 h under agitation. Wells 
were washed four times with PBS-T and a secondary HRP-labelled anti-mouse Ig antibody, 
that was also included in the ABAP kit (MQR), was diluted 1:2000 in PBS-1% BSA and 
200 µl were added. Strips were incubated again for 2h at RT under agitation. Afterwards, 
wells were washed four times with PBS-T and 200 µl TMB substrate was added. Reaction 
was stopped with 50 µl 2 M H2SO4. Finally, OD was measured at 450 nm. 
 
 
3.4.4 Stimulation of IEC and determination of NO production 
 
Undifferentiated Caco-2 cells were seeded for differentiation into 12-well tissue culture 
plates. Seventeen to twenty-one days post-confluence, 8 x 10
5 
cells were washed with pre-
warmed PBS and finally stimulated with 500 µl MEM20 Caco-2 growth medium supplement 
with a cytokine mixture containing 25 ng IL1-β/well, 50 ng TNF-α/well and 50 ng IFN-γ/well 
or with 500 µl Caco-2 growth medium alone. To measure NO formation over time, cell-free 
supernatants were collected after different time point’s and stored at -70°C until further 
processing. Total nitrite concentration was then determined using the Nitric Oxide 
Colorimetric Assay Kit according to the manufacturer’s manual (BioVision, Milpitas, USA). 
The kit was used because formed NO is unstable and oxidizes to nitrite (NO2
−
) that is further 
oxidized to nitrate (NO3
−
). First, in a two-step process, NO3
−
 is reduced NO2
−
 by a nitrate 
reductase. In the second step, the nitrite is then converted into a deep purple azo compound 
that can be measured photometrically at 540 nm. Thereby, the amount of the azochromophore 
reflects the NO amount within samples. 
To determine the NO formation by Caco-2 cells upon contact with trophozoites, differentiated 
Caco-2 cells were washed with PBS. Trophozoites cultures of different patient isolates as well 
as the laboratory strain WB-C6 were washed with PBS, incubated on ice for 30 min and 
harvested by centrifugation (900 x g, 5 min, 4°C). After a further washing step in PBS, 
trophozoites were resuspended either in Caco-2 growth medium or in Caco-2 growth medium 
supplemented with a cytokine mixture (25 ng IL1-β/well, 50 ng TNF-α/well, 
50 ng IFN-γ/well). After counting of trophozoites, 8 x 105 Caco-2 cells were infected with 
2.7 x 10
5
 parasites (MOI of 0.33) or 24 x 10
5
 parasites (MOI of 3) within 500 µl of 
appropriate medium. After 28 h incubation, supernatants were collected and total NO2
−
 was 
determined. 
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3.5 Descriptive statistics 
 
Data are given as means ± standard deviations (SDs). Statistical significance was assessed by 
paired (two-tailed) t test. All analyses were performed with GraphPad Prism 5 software 
(GraphPad Software, Inc., USA) with a statistical significance level of P < 0.05. 
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4 Results 
 
The ADI is known to be released by G. duodenalis upon contact with IEC in vitro and in vivo 
(Ringqvist et al., 2008). To address the question whether G. duodenalis ADI is a potential 
virulence factor, its enzyme characteristics and its influence on human host cells were 
investigated. The following experiments had focus on both: the native form occurring 
naturally in G. duodenalis lysates and the recombinant, purified form that was obtained after 
expression in E. coli. 
 
 
4.1 Generation of recombinant G. duodenalis ADI and its catalytically inactive mutant 
  
4.1.1 Expression of recombinant proteins 
 
Both recombinant proteins, ADI and ADIC424A, were generated with the purchasable 
StarGate
®
 cloning system. Although confidential, as underlying strategy the ‘Golden Gate’ 
cloning technology described by Engler et al. (2008) is presumed. The system allows a rapid 
transfer of any GOI from an entry vector into an expression vector by using Type II restriction 
endonucleases. For this study, in a first one-tube reaction the ADI-coding sequence, that was 
amplified from genomic G. duodenalis WB-C6 DNA by PCR, was inserted into an entry 
vector. In a second one-tube reaction, the formed donor vector was used together with the 
provided acceptor vector pASG-IBA35 for the generation of the destination vector 
pASG-IBA35+ADI that enables the expression of the recombinant protein with an 
N-terminal His6-tag in E. coli (Fig. 4). 
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Figure 4: Cloning of G. duodenalis arcA gene into the expression vector pASG-IBA35 
Shown is a schematic representation of the acceptor vector pASG-IBA35 before (A) and after insertion of the 
ADI coding sequence (B). A section of the plasmid map from the expression vector pASG-IBA35+ADI is 
illustrated in C. In the gene expression cassette tetP, His6-tag, ADI and restriction sites are highlighted. tetP (tet 
promoter); MCS (multiple cloning site); AmpR (ampicillin resistance gene); f1 and ColE1 ori (origin). 
 
 
 
The destination vector pASG-IBA35+ADI carried the inducible promoter/operator region of 
the tetA resistance gene (Tet-on system) to allow the regulated expression of the recombinant 
protein. The constitutive expression of the tet repressor gene, that was also encoded on the 
expression plasmid, ensured the repression of the promoter by binding on the operator in 
absence of the inducer. In contrast, addition of AHT fully induced the tet promoter and 
allowed protein expression.  
Further experiments required the generation of a control plasmid. The fusion protein of the 
expression vector pASG-IBA35+ADI was removed by XbaI/HindIII restriction digest, the 
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resulting overhangs were filled with Klenow fragment and the plasmid was ligated. By 
removal of the inserted ADI coding sequence, the His6-tag was deleted. The resulting plasmid 
was termed pASG-IBA35 (w/o His6-tag).  
Furthermore, a catalytically inactive mutant of the recombinant ADI was generated. It was 
previously described that the ADI of several other organisms uses an active-site cysteine for 
hydrolysis of arginine (Lu et al., 2004; Galkin et al., 2005; Li et al., 2009). Thus, the cysteine 
at amino acid sequence position 424 was exchanged to alanine by site-directed mutagenesis 
using the destination vector pASG-IBA35+ADI as template. 
After transformation into E. coli, both destination vectors pASG-IBA35+ADIC424A and 
pASG-IBA35+ADI were verified by restrictions digest and additionally by sequencing. 
The aim of protein expression is to obtain an intact product with high purity in high yield. The 
latter can be influenced by the biological properties of the expression strain as well as the 
protein characteristics itself. To sufficiently generate recombinant ADI and ADIC424A, 
different E. coli strains were tested for their ability to express the proteins. The genotypes of 
the used bacterial strains are summarized in Tab. 6. Exemplarily, E. coli strains transformed 
with the destination vectors pASG-IBA35+ADI and, as control, with 
pASG-IBA35 (w/o His6-tag) were grown to OD600 of ~ 1.5 and were induced with AHT for 
20 min. One ml of each bacterial culture was taken before and after induction and compared 
in Western blot analysis with each other. Obviously, the induction of G. duodenalis ADI 
expression in all E. coli strains led to occurrence of degradation products. The rate of 
degradation compared to ADI expression differed amongst the strains and is summarized in 
Tab. 14. The AHT-induced E. coli DH5αZ1 strain revealed the highest ADI expression with 
no or minimal degradation.       
 
Table 14: Summary of different E. coli strains tested for G. duodenalis ADI expression 
Different E. coli strains entailed varied rates of ADI degradation after induction of gene expression. To quantify 
degradation rate for each strain, the anti-His signal obtained for ADI was related to the overall anti-His signals 
obtained in Western blot. Degradation grade: + low (> 0.55); ++ middle (0.45-0.55); +++ high (< 0.45). 
     
 
 
 
 
 
 
 
 
E. coli strain Degree of degradation  
DH5αZ1 + 
ER2508 +++ 
JWK clpX-1 +++ 
XL1-Blue ++ 
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Interestingly, ADI was expressed by DH5αZ1 cells that were grown under noninduced 
conditions (Fig. 5), i.e. AHT was absent and in consequence the tet promoter blocked. 
Additionally, induction with AHT did not lead to remarkably increased amounts of produced 
recombinant protein in comparison to noninduced E. coli cells. These effects seemed to be 
independent from the activity of the ADI because same observations were made for the 
catalytically inactive mutant. To date, the reason for this phenomenon remained still unclear. 
Mistakes in the DNA sequence of the promoter, that could e.g. prevent binding of the 
repressor, were excluded by sequencing of the region.  
It was decided to express both recombinant proteins a) under noninducing conditions to 
minimize the risk for degradation and therefore obtain functional proteins and b) within the 
DH5αZ1 strain to obtain maximum yield. 
 
 
 
 
Figure 5: Induced and noninduced expression of recombinant protein 
E. coli DH5αZ1 strain was transformed with expression vector pASG-IBA35+ADI, pASG-IBA35+ADIC424A or 
the empty vector pASG-IBA35 (w/o His6-tag) as negative control. At OD600 between 1.4-1.6, bacteria were 
either induced for 20 min with 200 ng/ml AHT (+) or not (-). Samples were taken and 40 µg cell lysate per lane 
were loaded for SDS-PAGE (A) and for Western blot analysis (B). Immunoblot was developed with an antibody 
raised against the His-tag. 
 
 
4.1.2 Protein purification and characterization of recombinant proteins 
 
Prior to purification, ADI and ADIC424A were identified to be expressed as soluble proteins in 
the cytoplasm of E. coli DH5αZ1 (data not shown). Thus, it was sufficient to harvest 
E. coli culture and to directly disrupt the resuspended bacterial pellets with a High-pressure 
homogenizer. After centrifugation of cell debris, bacterial lysates were loaded onto columns 
prepacked with precharged Ni Sepharose that allowed one-step purification of the 
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His6-fusion proteins with the ÄktaFPLC system. After binding of the sample, nonspecifically 
bound molecules were removed by washing with buffer that included 70 mM imidazole. 
Finally, recombinant proteins were eluted with buffer including 200 mM imidazole. To 
prevent influence of imidazole on ADI activity and host cells in future experiments, the 
substance was remove after affinity chromatography. One effective method to remove low-
molecular weight compounds is dialysis. Unfortunately, most of the ADI and ADIC424A 
protein aggregated and became insoluble during this procedure. An alternative was to use 
desalting columns where imidazole was removed by gel filtration. Thereby, impurities were 
separated and buffer exchanged to PBS. Remaining traces of LPS, that is known to be a 
stimulus for immune cells, were removed with EndoTrap® columns. Finally, ADI and 
ADIC424A were concentrated with Vivaspin concentrators, aliquoted and stored at -70°C until 
further use.  
After protein purification, both enzymes were characterized. First, success of purification 
procedure was verified by SDS-PAGE and Western blot. In Fig. 6, a representative analysis of 
a purification experiment (here shown exemplarily for ADI) is summarized.  
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Figure 6: Purification of recombinant G. duodenalis ADI  
(A) Shown is a representative chromatogram obtained after purification of ADI. Left y-axis reflects absorbance 
at 280 nm expressed in mAU. Right y-axis shows the variation in buffer B concentration (100% are equal to 1 M 
imidazole) that allowed a gradual purification. (B) During purification, fractions were collected and those 
containing the recombinant protein were analyzed in SDS-PAGE and (C) Western blot. SDS gel was stained 
with Coomassie and immunoblot was developed with an antibody against the His-tag. Fraction with the highest 
peak (F3) was used for further experiments. mAU: milli-absorbance unit; F: Fraction; M: Marker; L: Lysate. 
 
 
Single fractions obtained during affinity chromatography were analyzed on SDS-PAGE 
(Fig. 6B) and in Western blot using an anti-His antibody (Fig. 6C) to confirm high purity and 
specificity of the 64 kDa recombinant protein in the main elution peak.  
Second, to determine the yield of the purification process and to further characterize the 
recombinant enzymes, protein concentration as well as catalytic activity was measured. For 
determination of enzymatic activity arginine served as substrate and its conversion into 
citrulline was determined by a colorimetric assay. The yield of the purification procedure and 
the enzymatic characterization of the recombinant ADI are summarized in Tab. 15.  As 
consequence of low expression, at least two liters of E. coli DH5Z1 cells carrying the plasmid 
pASG-IBA35+ADI were harvested to obtain recombinant protein in sufficient amounts. 
Activity for recombinant ADI was measured with approximately 7.7 U/ml which equals 
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11.6 U/mg. The specific activity of purified recombinant ADI varied between different 
purifications from 7 to 12 U/mg. 
Recombinant ADIC424A was analyzed identically. As expected, the mutated enzyme was 
catalytically inactive and could serve in the following experiments as negative control.  
 
 
Table 15: Summary of one-step purification of recombinant G. duodenalis ADI  
Characterization of affinity purified ADI from 2 l E. coli DH5αZ1 culture is shown. Protein amount was 
determined by BCA assay and as substrate for the enzyme activity assay arginine was used. U is defined as µmol 
substrate/min at 37°C in Hepes buffer. 
 
 
 
The recombinant ADI was used for the generation of polyclonal antibodies. An alpaca was 
immunized four times (days 0, 21, 35, and 49; Preclinics, Potsdam, G) with 300 μg of purified 
recombinant enzyme resuspended in 100 μl PBS plus adjuvant (complete Freund’s adjuvant 
for the first injection and incomplete Freund’s adjuvant for subsequent booster injections). 
Pre-immune serum was collected prior to the first immunization. After the last booster 
injection, the antiserum was obtained. Antigenic specificity of the polyclonal antiserum was 
tested in Western blot analysis (Fig. 7). The anti-G. duodenalis ADI antiserum identified both 
64 kDa recombinant proteins and revealed that both behaved similarly to the endogenous ADI 
parasite protein included in G. duodenalis lysate.  Preimmune serum, used as a control, did 
not react with any G. duodenalis protein (data not shown). 
 
 
 
 
 
 
 
 
 
 
Protein  
[mg]  
Volume 
[ml]  
Volume activity 
[U/ml]  
Total 
U  
Specific 
activity 
[U/mg]  
Enrichment  
(X-fold)  
Yield 
[%]  
Crude 
extract 
218 40.0 0.5 17.8 0.08 - 100 
Purified 
protein 
1.0 1.5 7.7 11.6 11.6 145 65 
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Figure 7: Western blot analysis of purified recombinant and native G. duodenalis ADI 
by polyclonal antiserum  
Antigenic identification of 0.5 µg affinity-purified recombinant ADI (lane 1), 0.5 µg catalytically inactive 
ADIC424A (lane 2) and native ADI in 2.9 µg G. duodenalis strain WB-C6 lysate (lane 3) by Western blotting with 
alpaca polyclonal antiserum raised against ADI.  
 
 
4.2 Recombinant G. duodenalis ADI and its influence on host immune response  
 
4.2.1 Recombinant G. duodenalis ADI had no PAD activity 
 
Posttranslational modification of a protein can affect its folding and thereby can influence its 
function directly or indirectly. Exemplarily, such a modification is the enzymatic deimination 
of intrapeptidic arginine into citrulline, termed citrullination. This enzymatic reaction is 
catalyzed by PADs and can lead to an altered three-dimensional protein structure that in 
consequence result in changes of its antigenic properties. Such citrullinated proteins are not 
longer recognized as endogenous but instead were noticed as foreign by the human immune 
system. In consequence, autoantibodies are generated, an inflammatory immune response is 
initiated and in long term an autoimmune disease develops. One example is rheumatoid 
arthritis, that causes destruction of joints and adjacent tissue, where e.g. citrullinated vimentin 
is described to play an important role in its pathogenesis (Van Steendam et al., 2010; 
Sanchez-Pernaute et al., 2012; Bicker and Thompson, 2013). 
In previous work, Touz et al. (2008) identified that recombinant ADI purified from 
G. duodenalis trophozoites had a PAD activity and therefore was able to deiminate arginine 
within the conserved CRGKA tail of VSPs. This posttranslation modification could have 
serious consequences for the host immune response after giardial infection. First, 
citrullination of free proteins by ADI could lead to the formation of noval B and T cell 
epitopes on host cells. Second, modification of membrane-bound receptors of immune cells 
that are in close surrounding to the released ADI (like DC branching between epithelial cells) 
could directly affect cells’ immunological function.  
Results 
57 
 
A PAD activity-ELISA was performed to test whether the recombinant ADI purified from 
E. coli catalyzes not only the conversion of free arginine into citrulline but also deiminates 
intrapeptidic arginine. Therefore, same conditions and substrate described by Touz et al. 
(2008) were used. A synthetic peptide H6-CRGKA was immobilized on Ni-NTA HisSorb 
Strips. The substrate was incubated with recombinant ADI and ADIC424A, G. duodenalis lysate 
and, as positive control, with human PAD for 16 h at 50°C. The results of one experiment 
with three technical replicates are shown in Fig. 8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Investigation of G. duodenalis ADI for PAD activity  
Recombinant ADI (200 mU) as well as native ADI (4 mU) from G. duodenalis WB-C6 lysates were tested for 
their ability to citrullinate intrapeptidic arginine in a peptide corresponding to the VSP-tail in ELISA. 
Recombinant human PAD (25 mU) served as positive control. Bars represent the mean ± SD from three 
technical replicates of one experiment. nc, negative control.  
 
 
Using an antibody raised against deiminated arginine revealed only citrullination of the 
VSP-tail by the positive control. Although, recombinant ADI was added in excess compared 
to the human PAD, no citrullination was detected at all.  
The catalytic activity of native ADI in parasite lysates to convert free arginine into citrulline 
was detected. However, the amount of ADI in this lysates was limited. Despite concentrating 
a large number of trophozoites, addition of native enzyme to the PAD activity-ELISA up to 
25 mU, similar to the positive control, was not possible. Thus, it is not clear whether there is 
no PAD activity of the native ADI or if the activity is below the detection limit of the assay. 
In future experiments the positive control should be diluted to a level similar to the ADI 
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activity in the lysate. Where, if at all, native ADI had only negligible PAD activity, 
recombinant ADI however seemed to have none. 
 
 
4.2.2 Recombinant G. duodenalis ADI had immunomodulatory effects on human DC 
 
The host’s innate immunity plays an important role in parasite clearance mechanisms. In 
giardial infection, DC as APC were identified to be critical for host defense (Kamda and 
Singer, 2009; Kamda et al., 2012). Due to projection of cellular extensions between epithelial 
cells into the lumen of the gut, DC can come into close contact to the parasite. The functional 
properties of these innate immune cells depend on the environment in which they are 
activated. Thus, it was hypothesized that ADI released by G. duodenalis trophozoites changes 
the DC surrounding milieu by consumption of arginine. If such a pathogen-mediated arginine 
depletion affects DC function and in consequence alters the subsequent stimulation of the 
adaptive immune response, e.g. the activation of T cells, is unknown so far.  
The following experiments should investigate whether the phenotype of human moDC, 
especially regarding cell surface markers and cytokine secretion, is influenced by recombinant 
G. duodenalis ADI activity in vitro.  
 
 
4.2.2.1 Preparation of human moDC 
 
To model conditions in the intestine and investigate potential immunomodulatory effects of 
ADI activity on DC function, human moDC were prepared. Therefore, CD14-positive cells 
were isolated from human buffy coat by density gradient centrifugation and subsequent 
magnetic-activated cell sorting. Typically, cells were thereby enriched to 
≥90% CD14-positive cells as determined by flow cytometry. Afterwards, these cells were 
differentiated with human recombinant GM-CSF and IL-4 to obtain moDC (Fig. 9). After 6 
days, immature DC were harvested and the cell population was characterized by analyzing an 
aliquot by flow cytometry. Staining of surface markers revealed consistence with DC 
phenotype that means low levels of CD14 and CD86 and high levels of HLA-DR, whereas 
CD25 and CD83 were not expressed (data not shown). 
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Figure 9: LM-micrograph of human moDC 
(A) Nonstimulated human CD14-positive cells isolated from human buffy coat did not show DC phenotype after 
six days of cultivation. (B) In contrast, same cells differentiated into immature moDC in six days when treated 
with 1000 U/ml human rGM-CSF and 10 ng/ml human rIL-4.  
 
 
 
4.2.2.2 Definition of experimental conditions for arginine depletion by recombinant, 
enzymatically active ADI during DC activation in vitro 
 
The amino acid arginine is known to play important roles during immune responses. For 
example, arginine affects T cell function (Zea et al., 2004) and is used by NOS as substrate to 
generate anti-microbial NO. Depletion of arginine is known to be a strategy of pathogens to 
evade the host’s immune defense. Thus, as part of their virulence mechanism, pathogens 
successfully compete with the host for arginine e.g. by enzymes like arginases (Bronte and 
Zanovello, 2005; Das et al., 2010).  
To investigate whether G. duodenalis ADI as potential virulence factor changes the response 
of DC by arginine depletion, the effect of ADI activity on the amount of arginine that may be 
available to the parasite during an infection was estimated and the experimental conditions to 
study the consequences of ADI activity on activated moDC in vitro were defined. The average 
daily intake of arginine by humans has been estimated to be 5 g, which corresponds to 
28 mmol (Böger, 2007). It has been reported that an infected person sheds up to 
10
9
 G. duodenalis organisms per day (Danciger and Lopez, 1975). The ADI activity per 
million trophozoites was determined to be equivalent to approx. 0.02 U by preparing lysates 
from the laboratory strain WB-C6 and determining the ADI activity (Tab. 16). Therefore, at 
least 20 U of enzyme may be produced per day of infection. One U corresponds to 1 µmol 
arginine metabolized per minute, hence > 28 mmol could potentially be turned over in one 
day. Thus, infection with Giardia has the potential to substantially deplete the arginine in the 
gastrointestinal tract. To achieve arginine depletion by recombinant ADI in a standard 24-h 
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DC stimulation assay that enables to study the consequences of arginine depletion on DC, 
enzymatically active enzyme should be added gradually. Theoretically, 4 µg (corresponding 
to 30 mU and representing the equivalent of the enzymatic activity of two to three 
trophozoites per DC present in the study) of active recombinant ADI converts all of the free 
arginine in 43 min (culture volumes of 1 ml RPMI containing 1.15 mM arginine), 10-fold less 
enzyme in approximately 7 h and 100-fold less enzyme in nearly 72 h, assuming constant 
activity over time (Fig. 10A). To study dose dependence in the following DC activation 
experiments, these serial dilutions of active enzyme were used as well as the catalytically 
inactive mutant form to control for possible effects unrelated to enzyme activity.  
The theoretically calculated consumption of arginine by ADI was verified experimentally. 
Therefore, harvested immature DC were counted and 5 x 10
5 
cells/well were seeded in 
12-well tissue culture plates. Cells were stimulated with 1 µg/ml or 10 ng/ml LPS and 
exposed to the mentioned concentrations of ADI and equal amounts of the mutant enzyme. 
After 24 h supernatants were collected and citrulline formation was determined by a 
colorimetric assay. The results are shown in Fig. 10B. The predicted, calculated effect of 
recombinant ADI on arginine turnover was almost absolutely confirmed experimentally. 
Enzyme concentrations of 4 µg or 0.4 µg led to a citrulline formation of 0.87 mM ± 0.22 
(n = 7) and 0.84 mM ± 0.21 (n = 7) respectively and therefore to arginine depletion at the end 
of the 24-h assay period. As expected, activity of 40 ng ADI, the amount of enzyme that 
required 72 h to turnover all arginine, formed roughly 30% of the maximal level reached by 
both other enzyme concentrations. Thus, under these experimental conditions the majority of 
the enzyme retained pro-longed activity.  
Addition of ADIC424A at all of the concentrations tested did not result in any specific citrulline 
formation (Fig. 10B and data not shown).  
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Figure 10: Recombinant ADI converts medium arginine  
(A) Theoretic calculation of time being necessary to convert the entire arginine from 1 ml DC growth medium 
by recombinant ADI. (B) For experimental verification, immature moDC (5 x 10
5
 per well of a 12-well tissue 
culture plate) were treated with a gradual dilution of 4 µg (equal to 30 mU) recombinant ADI or, as a control, 
corresponding levels of catalytically inactive ADIC424A (only largest amount is shown) and were exposed to LPS 
(here 1µg/ml). Citrulline content in supernatants was determined as a measure of the cumulative ADI activity 
and arginine depletion over the 24-h assay time. Bars represent the mean ± SD from experiments with DC 
prepared from seven different donors.  
 
 
4.2.2.3 Enzymatic arginine depletion by ADI modifies pro- and anti-inflammatory 
cytokine secretion of LPS-activated moDC 
After confirming citrulline formation by ADI, collected supernatants were used to study the 
consequences of arginine depletion on moDC. Therefore, cytokine concentrations in the 
supernatants were determined by ELISA. The results are represented in Fig. 11. Activation of 
cells with 1 µg/ml LPS stimulated roughly a 100-fold and with 10 ng/ml LPS a 50-fold 
increase in IL-12p40, TNF-α and IL-10 levels in arginine-replete medium compared to those 
in nonactivated controls (data not shown). In contrast, LPS-stimulated (1 µg/ml) moDC 
exposed to 4 µg/ml of ADI produced significantly less IL-10 and IL-12p40. These values 
were 45% (P < 0.001, n = 7) and 17% (P < 0.01, n = 6) lower than those of control cells 
exposed to mutant ADIC424A, respectively. In contrast, TNF-α secretion by ADI-treated and 
LPS-activated moDC was increased and values were, on average, 74% (P < 0.01, n = 6) 
higher than the values of LPS-stimulated, mutant enzyme exposed-control cells (Fig. 11A).  
MoDC that were stimulated with 10 ng/ml LPS showed for all three cytokines similar results 
compared to cells being activated with a higher LPS concentration (Fig. 11B). Of note, 
decreased IL-10 and IL-12p40 levels were also observed with 10-fold less ADI present 
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whereas increased TNF-α was observed only at the higher enzyme concentration, indicating 
that the time required by different doses of the enzyme to deplete arginine was relevant. These 
data show that arginine depletion by ADI modulates the pro- and anti-inflammatory cytokine 
secretion of LPS-activated moDC and, importantly, that the effects differ, depending on the 
cytokine analyzed.  
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Figure 11: Enzymatic arginine depletion by ADI modulates cytokine secretion of LPS-
activated human moDC 
Immature moDC (5 x 10
5
 per well of a 12-well tissue culture plate) were exposed to the indicated amounts of 
recombinant ADI or, as a control, corresponding levels of ADIC424A (only the largest amount is shown), and 
1 µg/ml (A) or 10 ng/ml (B) LPS was added. After 24 h, DC cytokine secretion into supernatants was assessed 
by ELISA and is expressed as a percentage of the amount secreted by LPS-stimulated cells not exposed to any 
ADI protein. Symbols represent values from individual donors, and means are indicated by horizontal lines.  
Differences between the amounts of cytokines secreted by cells exposed to mutant (control) or active ADI were 
analyzed by paired (two-tailed) t test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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4.2.2.4 Enzymatic arginine depletion by ADI reduces upregulation of surface CD83 and 
CD86 levels of LPS-activated moDC 
 
To investigate the influence of arginine depletion by ADI activity on the phenotype of 
maturing DC, moDC were stimulated with LPS and treated with ADI or the mutant form 
ADIC424A as described above and were analyzed for selected surface marker protein levels by 
flow cytometry. Activation of immature moDC with LPS induced upregulation of CD83 and 
CD86 (Fig. 12A and data not shown) as expected. In contrast, moDC stimulated with 1 µg/ml 
LPS and treated with arginine-depleting levels of ADI expressed significantly less CD83 and 
CD86 than did control cells. Surface CD83 was, on average, 22% (P < 0.05, n = 3) and CD86 
was 15% (P < 0.01, n = 4) lower than on LPS-treated, mutant enzyme-exposed control cells. 
The effects were again ADI dose dependent (Fig. 12B). These results were confirmed by 
using 10 ng/ml LPS as stimulus for the moDC (Fig. 12C). The reduced upregulation of 
surface CD83 and CD86 unlikely reflects a general effect on surface protein levels since 
HLA-DR abundance on LPS-activated moDC was not affected by ADI (data not shown).  
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Figure 12: Enzymatic arginine depletion by ADI reduces CD83 and CD86 surface 
marker levels on LPS-activated moDC 
Cells were treated as described in the legend to Fig. 11, and all the cells, except the nonstimulated control cells, 
were treated with 1 µg/ml (B) or 10 ng/ml (C) LPS. After incubation for 24 h at 37°C, moDC were harvested, 
stained with cell surface marker-specific antibodies, and analyzed by flow cytometry. (A) Representative dot 
plots for CD14/CD83 (top) and CD25/CD86 (bottom) expression (here: stimulated with 1µg/ml) with the 
respective mean fluorescence intensity (MFI) values for CD86- and CD83-positive populations (cells in the 
lower right and top left quadrants of panel A) are shown. wo, without. (B, C) Relative MFI values as percentages 
of those of control LPS-stimulated cells for CD83 (n = 3) and CD86 (n = 4) with moDC from different donors 
are shown. Horizontal lines correspond to mean values, and differences between the respective MFI values on 
cells exposed to mutant (control) or active ADI were analyzed by paired (two-tailed) t test. *, P < 0.05; 
** P < 0.01. wo, without. 
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4.2.2.5 ADI immunomodulatory effects on LPS-activated moDC result from both 
arginine depletion and product formation 
 
Next step was to investigate whether the modulatory effects of ADI on the moDC functional 
phenotype resulted from arginine depletion and/or the formation of the ADI reaction products 
citrulline and/or NH4
+
. To investigate possible cause-effect relationships, moDC were 
generated as described, harvested, and seeded into arginine-free culture medium that was 
subsequently supplemented with 2 mM or 0.2 mM arginine, citrulline, and/or ammonium 
chloride, respectively. The supplementation of 2 mM was chosen in accordance to the primary 
experiment with complete growth medium, whereas 10-fold fewer supplements were added to 
test whether the resultant effects depend on the amount of reaction products. Cells were 
treated as before with 4 µg of ADI or ADIC424A and activated with 1µg/ml LPS. After 24 h of 
incubation, supernatants were collected and citrulline content and cytokine concentration were 
determined. Determination of citrulline formation in cell culture supernatants confirmed on 
the one hand functional ADI activity and on the other hand served as control for precise 
supplementation (Fig. 13). NH4
+
 formation by ADI was also determined in culture 
supernatants, and levels were comparable to those observed after supplementation with 
ammonium chloride (data not shown). Furthermore, moDC were harvested and cell surface 
markers were analyzed.  
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Figure 13: About 75% of supplemented or by recombinant ADI produced citrulline was 
detectable in cell culture supernatants 
After harvest immature moDC were seeded into arginine-free growth medium. The medium was supplemented 
as indicated with 2 mM (A) or 0.2mM (B) arginine, citrulline and/or ammonium  chloride (brackets indicate 
addition of ADI to arginine-replete medium to reflect formed, not supplemented products). Cells were activated 
with 1 µg/ml LPS and treated with 4 µg ADI (●) or mutant ADIC424A (○) for control. After 24 h, supernatants 
were taken and citrulline formation determined by colorimetric assay. Figures show only supernatants of LPS-
activated, treated cells. Bars represent the mean ± SD from experiments with DC prepared from three different 
donors.  
 
 
IL-10 and TNF-α secretion of cells grown in medium including 2 mM arginine were 
modulated as described above, i.e. ADI-treated LPS-activated moDC produced less IL-10 and 
more TNF-α than did control cells. Also the analysis of the surface markers CD83 and CD86 
of moDC confirmed the previous obtained phenotype after addition of ADI (Fig. 14A). 
MoDC stimulated in the absence of arginine showed a small decrease in IL-10 production, but 
levels remained significantly higher than those of cells treated with ADI in the presence of 
arginine, where citrulline and NH4
+ 
could be formed. The addition of the ADI products, in 
particular of NH4
+ 
in the form of NH4Cl, reduced IL-10 levels to those observed in the 
presence of arginine and ADI. Similarly, CD83 and CD86 surface levels were also reduced, 
although this did not reach statistical significance for the latter marker. In contrast, the 
increase in TNF-α production was driven mainly by arginine depletion. LPS-activated DC 
from all of the donors tested showed significantly increased TNF-α production in the absence 
of arginine (P < 0.01; n = 8), with cells from some donors reacting particularly strongly, 
producing nearly three times as much as the respective control DC (data not shown and 
Fig. 14A). The increase due to arginine depletion was not affected by NH4
+
 but reduced by 
citrulline, indicating that citrulline could substitute for arginine in this respect (Fig. 14A). By 
addition of 0.2 mM supplements the described results for addition of 2 mM supplements 
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could be confirmed but differences did not reach statistical significance (Fig. 14B). Thus, it 
seems to be that the amount of reaction products that were developed in consequence of ADI 
activity had an impact on the occurrence of the respective phenotype. 
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Figure 14: Depletion of arginine and formation of ADI reaction products citrulline and 
ammonium ions modulate the moDC response to LPS activation 
Immature moDC were seeded into arginine-free growth medium. Medium was supplemented as indicated with 
2 mM (A) or 0.2 mM (B) arginine (Arg), citrulline (Cit) and/or ammonium chloride (brackets indicate addition 
of ADI to arginine-replete medium to reflect formed, not supplemented products). Cells were activated with 
1µg/ml LPS and treated with 4 µg ADI (●) or mutant ADIC424A (○) as a control. Continued on next page. 
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Values correspond to percentages of the respective parameter determined for cells stimulated with LPS only in 
arginine-replete medium. After 24 h, supernatants were collected and cytokine concentrations were determined 
by ELISA. MoDC were harvested and CD83 and CD86 surface markers were analyzed by flow cytometry. 
Horizontal lines correspond to mean values, and differences between the respective parameter determined with 
cells exposed to mutant (control) or active ADI were analyzed by paired (two-tailed) t test. *, P < 0.05; 
**, P < 0.01. 
 
The importance of ammonium ions as reaction product was additionally confirmed by 
supplementing moDC with NH4
+
 during stimulation in the presence of arginine but in absence 
of ADI. IL-10 was reduced, but no effect on TNF-α production was noticeable (Fig. 15). 
Thus, the immunomodulation of moDC by ADI resulted from a combination of distinct 
effects of arginine depletion and/or citrulline and NH4
+
 product formation.  
 
 
 
 
 
 
 
 
 
 
Figure 15: NH4
+
 reduces IL-10 secretion by LPS-stimulated moDC 
Immature moDC were prepared and stimulated with LPS as described in the legend to Fig. 14 in medium 
supplemented with either 2 mM arginine alone (control) or arginine plus NH4Cl (2mM each). After 24 h, 
cytokine concentration was determined from supernatants by ELISA. Cytokine concentrations are expressed as 
percent differences from the cytokine amounts produced by control cells. Each dot represents an independent 
experiments with moDC prepared from an individual donor. Significance was tested against the null hypothesis 
that addition of NH4
+
 had no effect by paired (two-tailed) t test. P values were (P < 0.01) for IL-10 levels and 
nonsignificant (P > 0.05) for TNF-α levels. 
 
 
4.2.2.6 NH4
+
 and urea, the reaction products of ADI and arginases, differ in their effect 
on cytokine secretion and the surface marker profile of LPS-stimulated moDC 
 
As mentioned before, many pathogens are thought to evade NO-mediated immune clearance 
through arginine depletion by arginases, which will result in the formation of ornithine and 
urea (Das et al., 2010). Immunomodulatory effects may thus be different from conditions 
where deiminases are relevant. Therefore, the immunomodulatory effects of NH4
+
 and urea as 
well as citrulline and ornithine were compared. LPS-stimulated cells were incubated for 24 h 
in medium devoid of arginine but supplemented with ammonium chloride, urea, citrulline or 
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ornithine, and then supernatants were collected for the detection of IL-10 and TNF-α by 
ELISA (Fig. 16A) and of CD83 and CD86 proteins by flow cytometry (Fig. 16B). Notably, 
cells stimulated in medium supplemented with urea produced significantly more IL-10 and 
displayed significantly higher levels of CD83 and CD86 surface proteins than did cells 
stimulated in the presence of NH4
+
. In contrast and corroborating the findings that TNF-α 
production was not affected by NH4
+ 
(Fig. 15), no differences between cells treated with NH4
+
 
and urea were noted with respect to TNF-α release. The comparison of citrulline and ornithine 
supplementation revealed also no significantly differences, except for CD83 surface proteins, 
confirming that both reaction products had no effects on moDC phenotype.  
To sum up, within this experiment it was shown that NH4
+
 and urea, the reaction products of 
ADI and arginases, differ in their way to affect cytokine secretion and surface marker profile 
of LPS-stimulated moDC.  
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Figure 16: Immunomodulation of LPS-activated moDC undergoing arginine starvation 
is different between NH4
+
 and urea 
MoDC were prepared as described in the legend to Fig. 14 and stimulated in arginine-free medium supplemented 
either with 2 mM ammonium chloride, urea, ornithine or citrulline. After 24 h, supernatants were collected and 
cytokine concentrations were determined by ELISA (A). The moDC were harvested, and surface marker proteins 
were analyzed by flow cytometry (B). Dots represent values from experiments with cells from six (panel A) or 
four (panel B) individual donors and are expressed as percentages of control values obtained with LPS-activated 
cells with no supplement. *, P < 0.05 (paired [two-tailed] t test); ns, nonsignificant. 
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4.2.2.7 Arginine turnover by ADI results in decreased phosphorylation of the mTOR-
signaling pathway target S6K in LPS-activated moDC 
 
Previous studies suggested an inhibitory effect of branched-chain amino acids on the 
mTOR/S6K signaling pathway, resulting in impaired maturation of moDC and particularly 
affecting CD83 expression (Kakazu et al., 2007). mTOR is a serine/threonine kinase that is 
present in two distinct protein complexes, mTORC1 and mTORC2. Activation of mTORC1 
leads to the phosphorylation of the proteins S6 kinase (S6K) and the eukaryotic initiation 
factor 4E (eIF-4E) binding protein 1 (4E-BP1), which are both involved in the regulation of 
protein translation (Carrera, 2004). Arginine levels have been shown to affect mTOR 
signaling in several cell types (Ban et al., 2004; Yao et al., 2008). Since ADI by arginine 
depletion had immunomodulatory effects on moDC, involvement of the mTOR pathway in 
these cells was investigated. MoDC were seeded in arginine-free medium and then 
supplemented or not with arginine. The cells were treated with recombinant ADI or 
catalytically inactive ADIC424A or with the mTOR inhibitor rapamycin as a positive control 
and were activated with LPS. Cells were incubated for 24 h before determining surface CD83 
levels (Fig. 17A). In the presence of arginine, CD83 levels were lower on cells treated with 
ADI than on cells exposed to mutant enzyme, as shown before. MoDC stimulated in the 
absence of arginine or in the presence of arginine and rapamycin also showed reduced levels 
of CD83 protein (Fig. 17A).  
To investigate whether reduced CD83 surface levels caused by ADI activity correlated with 
mTOR signaling, treated cells were harvested 30 min after LPS stimulation to assess mTOR-
dependent phosphorylation events. Cells were lysed, and equal amounts of total protein were 
separated by SDS-PAGE. The abundance of phosphorylated mTOR target protein S6K was 
then determined by Western blotting (Fig. 17B), and results were quantified. First, Western 
blot signals obtained for S6K and 4E-BP1 from five independent experiments were related to 
signals obtain for the reference protein β-actin to ensure that same amounts of the effector 
molecule were available in all cases (Fig. 17C). Levels of total p70-S6K and 4E-BP1 were not 
significantly different between the distinct experimental groups. 
Second, signals obtained for phosphorylated S6K and 4E-BP1 were related to β-actin signals 
to identify if the arginine turnover by ADI results in decreased phosphorylation of these both 
mTOR-signaling pathway targets in LPS-activated moDC. In Fig. 17D results with cells from 
five independent donors are summarized and these show that suppression S6K 
phosphorylation in moDC correlated with reduced CD83 surface protein levels, and this 
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depended on arginine levels. Control cells treated with rapamycin showed the expected 
suppression of S6K phosphorylation. Contrary to literature (Haidinger et al., 2010), 
suppression of 4E-BP1 phosphorylation with rapamycin was not observed. A possible 
explanation is the different experimental setting. Using moDC, phosphorylation of 4E-BP1 
might be regulated by an alternative mTOR independent pathway. Adequate interpretation of 
the experimental results is difficult as they lack a positive control. Nevertheless, by trend, the 
mTOR/4E-BP1-signaling pathway in moDC did not seem to depend on arginine availability.  
These data suggest that arginine levels, similar to what has been shown for branched-chained 
amino acids (Kakazu et al., 2007), affect mTOR activity in moDC but also indicate a 
difference between amino acids. 
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Figure 17: ADI-mediated arginine depletion decreases mTOR signaling in LPS-
stimulated moDC 
Immature moDC (10
6
 in arginine [Arg]-free growth medium) were seeded in into each well of a 12-well tissue 
culture plate. Arginine-free medium (ΔArg) was supplemented or not with 2 mM arginine, and cells were treated 
or not with 4 µg of ADI, 4 µg of ADIC424A, or 2 µM rapamycin (Rapa). For activation, 1 µg/ml LPS was added to 
each sample after 2 h. (A) MoDC CD83 surface marker levels 24 h after stimulation and those of stimulated 
control cells are compared. Bars represent the mean ± SD of independent experiments with five different donors. 
*, P < 0.05 (paired [two-tailed] t test compared with the respective control). In parallel, 30 min after LPS 
stimulation, cells were harvested, washed, and lysed. A 50-µg sample of cell extract was separated by SDS-
PAGE, and p70-S6K,4E-BP1, phospho-p70-S6K, phospho-4E-BP1, and β-actin were detected by 
immunoblotting. One Western blot is exemplary shown in (B). Immunoblots were quantified by image analysis 
and p70-S6K or 4E-BP1 (C) and phospho-p70-S6K or phospho-4E-BP1 (D) levels were normalized relative to 
β-actin and compared to those of stimulated control cells. (C) Levels of total p70-S6K were not significantly 
different between the different experimental groups. Continued on next page. 
 
   CD83
0
50
100
150
*
*
*
         +             +             -              +
          -             +             -               -
         +              -             -               -
Arg
ADI
ADIC424A
          -              -             -              +Rapa
   Treatment
M
F
I 
(%
 o
f 
L
P
S
 c
o
n
tr
o
l)
0
100
200
300
         +             +             -              +
          -             +             -               -
         +              -             -               -
Arg
ADI
ADIC424A
          -              -             -              +Rapa
   Treatment
S
6
K
 (
%
 o
f 
L
P
S
 c
o
n
tr
o
l)
0
100
200
300
400
         +             +             -              +
          -             +             -               -
         +              -             -               -
Arg
ADI
ADIC424A
          -              -             -              +Rapa
   Treatment
4
E
-B
P
1
 (
%
 o
f 
L
P
S
 c
o
n
tr
o
l)
0
50
100
150
200
250
*
         +             +             -              +
          -             +             -               -
         +              -             -               -
Arg
ADI
ADIC424A
          -              -             -              +Rapa
   Treatment
**
P
-S
6
K
 (
%
 o
f 
L
P
S
 c
o
n
tr
o
l)
0
50
100
150
         +             +             -              +
          -             +             -               -
         +              -             -               -
Arg
ADI
ADIC424A
          -              -             -              +Rapa
   Treatment
P
-4
E
B
P
1
 (
%
 o
f 
L
P
S
 c
o
n
tr
o
l)
D
C
A B
Results 
76 
 
Bars represent the mean ± SD from five individual experiments with cells from different donors. *, P < 0.05; 
**, P < 0.01 (compared with the respective control by paired [two-tailed] t test). 
 
 
4.2.3 Influence of native ADI released by G. duodenalis trophozoites on Caco-2 cells 
 
Experiments of Ringqvist et al. (2008) where ADI was shown to be released by G. duodenalis 
WB-C6 trophozoites upon contact with Caco-2 cells supported investigations of human body 
fluids where the enzyme was noticed to be an immunoreative protein (Palm et el., 2003; 
Téllez et al., 2003). These findings spotlighted the enzyme to be implicated in virulence of 
G. duodenalis and thus being involved in host-parasite interplay. Further in vitro studies have 
shown that the G. duodenalis WB-C6 strain (Eckmann et al., 2000) itself as well as its 
recombinant ADI (Ringqvist et al., 2008) inhibited NO formation of human IEC by 
consumption of free arginine. To investigate, whether this phenomenon is strain-dependent 
and possibly related to its substrate affinities (Fig. 24B), the NO-dependent parasite clearance 
mechanism of Caco-2 cells was investigated. First, an in vitro model was established and 
release of native ADI by parasites was tested. Second, optimal stimulation conditions for NO 
production of Caco-2 cells were determined to subsequently investigate the effect of ADI 
release by G. duodenalis trophozoites on the NO production of epithelial cells.  
 
 
4.2.3.1 Usage of Caco-2 cells as in vitro model 
  
So far, no adequate animal model exists to investigate the influence of Giardia parasites on 
host immune responses in vivo. Several investigations were performed using an adult mouse 
model for infection. Colonization of the mouse small intestine was difficult and depended on 
both, the mouse and the parasite strain. Successful infection of adult mice with G. duodenalis 
strains causing human giardiasis was only possible with the two laboratory strains GS/M-H7 
and WB-C6 (Byrd et al., 1994; Solaymani-Mohammadi and Singer, 2011). 
However, investigations of other human G. duodenalis isolates are essential. As alternative to 
the in vivo mouse model, human Caco-2 cells as an intestinal epithelial tumor cell line were 
used for in vitro studies (Ringqvist et al., 2008; Maia-Brigagão et al., 2012; Stadelmann  et 
al., 2012). In vitro cultivated Caco-2 cells grow as confluent monolayer and undergo 
epithelial differentiation (Grasset et al., 1984) that results in morphological and functional 
features similar to small intestinal enterocytes (Ferruzza et al., 2012). During differentiation 
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the formation of tight junctions seals adjacent cells and thus creates intercellular boundaries. 
These cell-to-cell adhesion structures have protective (e.g prevent diffusion of solutes across 
the cellular sheet) and functional (e.g maintain cellular polarization) features (Alberts et al., 
2002). Tight junction assembly is mediated by junction-associated membrane proteins such as 
zonula occludens (ZO)-1 (Stevenson et al., 1986). In this study ZO-1 was used as a marker to 
verify tight junctions because of its structural and signalling roles during cell-cell contact 
formation (Anderson et al., 1989). 
Caco-2 cells were seeded into 12-well tissue culture plates and were cultured until confluence. 
After further 17-21 days in culture, cells were checked for development of cell-cell contacts 
by fluorescent staining (Fig. 18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: LM-micrograph of differentiated human Caco-2 cells 
Caco-2 cells grown for 17-21 days post-confluence were stained either with DiffQuik
®
 (A) to show cell 
morphology or with fluorescent-conjugated antibody directed against ZO-1 protein (B) to verify differentiation. 
Scale bar = 50 µm. 
 
 
Usage of an antibody raised against the ZO-1 protein revealed the formation of tight junctions 
in the monolayer. Thus, Caco-2 cells served as a useful model in the following experiments. 
  
 
4.2.3.2 Release of G. duodenalis ADI upon contact with Caco-2 cells is 
strain-independent 
 
To prove the hypothesis that ADI as a potential virulence factor is involved in host-parasite 
interplay, the observation of Ringqvist et al. (2008) needed to be confirmed. Thus, the release 
of ADI by G. duodenalis WB-C6 trophozoites but additionally the release by other 
G. duodenalis strains upon contact with Caco-2 cells was examined. Therefore, the 
Giardia biobank (4.3.1) provided a good opportunity to test for several clinical isolates that 
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were also of assemblage A, but had another subgenotype than the laboratory strain WB-C6. 
For this reason, Caco-2 cells in a tight monolayer were exposed to trophozoites of the 
different patient isolates and the laboratory strain WB-C6 as well. Three times more parasites 
than cells were added. Further cultivation allowed a quick attachment of the trophozoites to 
their host cells. After 45 min, cell-free supernatants were taken and released proteins were 
analyzed in Western blot (Fig. 19).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Release of native G. duodenalis ADI upon contact with Caco-2 cells 
Differentiated Caco-2 cells were infected (MOI of 3) either with trophozoites of strains collected in the Giardia 
biobank or of the laboratory strain WB-C6. After further cultivation for 45 min under aerobic conditions, 
cell-free supernatants were taken and included proteins precipitated. Total proteins were loaded on SDS-PAGE 
for Western blot analysis. Native ADI was detected by polyclonal alpaca antiserum raised against the enzyme.  
 
 
 
Addition of all strains to Caco-2 cells led to release of native ADI identified as ~ 64 kDa band 
in immunoblotting. Cell-free supernatants from trophozoites that were seeded in parallel in a 
12-well tissue culture plate without IEC showed no or rather a weak signal for ADI in 
Western blot analysis. That indicated a specific release of the enzyme after host-parasite 
contact. To clarify whether trophozoites of distinct strains release different amounts of ADI as 
a kind of virulence mechanism, lysis of the parasite during the experiment needed to be 
excluded. One possibility was to verify e.g. tubulin, an intracellularly located protein that is 
import for the arrangement of the cytoskeleton, in Western blot analysis. Unfortunately, it was 
not possible to distinguish between lysis of Caco-2 cells and parasites as both express 
eukaryotic tubulin. Alternatively, parasite lysis was verified by fluorescent cell staining. 
Substance of choice was CFDA-SE that enters the cytoplasm of cells and is cleaved by 
intracellular esterases to CFSE that reacts with intracellular molecules, forming fluorescent 
conjugates. Unfortunately, this approach was without any success (data not shown). Focusing 
on the Western blot analysis and considering the aspect that all samples were treated identical 
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and entire proteins were loaded on SDS-PAGE, by trend the laboratory strain WB-C6 
released more ADI than the other strains. 
 
 
4.2.3.3 G. duodenalis reduced NO formation of stimulated Caco-2 cells is strain-
independent  
 
The free radical NO is an important molecule for various biological functions in the body. NO 
and citrulline are formed by the conversion of arginine and oxygen by the enzymatic activity 
of NOS. There exist three different isoforms of NOS termed neuronal NOS (nNOS, or 
NOS1), inducible NOS (iNOS, or NOS2) and endothelial NOS (eNOS, or NOS3). The 
expression of iNOS is regulated by cytokines, whereas nNOS and eNOS are constitutively 
expressed and calcium-dependently regulated. NO acts as cellular signaling molecule in the 
cardiovascular and nervous system, on the other hand it has effector (e.g. antimicrobial and 
anti-tumor activity) and immunoregulatory functions (e.g. pro- or anti-inflammatory effects) 
in the immune system (Bogdan, 2001). In the latter, NO is generated by several cells, e.g. 
macrophages, DC, mast cells as wells as other cells involved in immune response like 
epithelial cells. Previously, it was shown that addition of recombinant G. duodenalis ADI 
with cytokines to differentiated Caco-2 epithelial cells impaired their NO formation by 
competing for arginine with iNOS (Ringqvist et al., 2008). Thus, the influence on the 
NO-dependent parasite clearance mechanism of Caco-2 cells was investigated with the 
collected G. duodenalis parasites, releasing ADI of different assemblage subtypes that differ 
in their substrate affinity for arginine compared to the laboratory strain WB-C6. 
First step was to determine the optimal stimulation conditions for Caco-2 cells to produce NO. 
Therefore, differentiated Caco-2 cells (seeded in a 12-well tissue culture plate) were treated 
with various cytokine mixtures including human TNF-α, IFN-γ and IL-1β in different 
concentrations. After 24 h, supernatants were collected and NO formation was determined as 
total nitrite within a colorimetric assay. The strongest stimulation and therefore the highest 
NO formation was reached with a concentration of  50 ng/well TNF-α, 25 ng/well IL-1β and 
50 ng (330 U)/well IFN-γ (data not shown). The next experiment was to determine the NO 
formation over time under the optimal cytokine concentrations. Therefore, Caco-2 cells were 
stimulated, cell-free supernatants were taken after certain time points and total nitrite was 
measured. Approximately 6 h after induction of iNOS, NO production was detectable and 
approximately 28 h after induction NO production reached its maximum (Fig. 20). In parallel 
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cultivated, nonstimulated Caco-2 cells showed no NO formation at all. For following 
experiments it was decided to take supernatants 28 h after induction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: NO formation over time after stimulation of Caco-2 cells 
Differentiated Caco-2 cells, that were initially seeded into a 12-well tissue culture plate, were stimulated or not 
with 25 ng IL1-β/well, 50 ng TNF-α/well and 50 ng IFN-γ/well. After certain time point’s cell-free supernatants 
were taken and total nitrite was measured in a colorimetric assay. Nonstimulated cells were not able to produce 
NO in detectable amounts. One representative experiment out of two is shown. Each bar represents the 
mean ± SD of three technical replicates. 
 
 
Under defined experimental conditions, the influence of substrate affinity on NO production 
was investigated for the native ADI of the laboratory strain WB-C6 and the clinical isolates 
collected in the Giardia biobank. Because of time deficit, it was only possible to perform this 
experiment once with three technical replicates. Caco-2 epithelial cells were stimulated or not 
with cytokines as described and were in parallel infected with three times more (MOI of 3) or 
three times less (MOI of 0.33) trophozoites of the various G. duodenalis strains. Cell-free 
supernatants were collected and total nitrite concentration was determined. It was observed 
that Giardia infection without cytokine stimulation did not result in NO formation by Caco-2 
cells. Under stimulating conditions, the addition of the laboratory strain WB-C6 in both MOIs 
showed impaired NO production in Caco-2 cells, as described in the literature (Eckmann et 
al., 2000). Same results were also obtained by infecting of IEC with other G. duodenalis 
strains. Interestingly, by using an MOI of 3 it was observed that by trend the isolates collected 
in the Giardia biobank and the laboratory strain WB-C6 differed in their ability to reduce NO. 
This might be due to differences in the substrate affinity. In contrast, for an MOI of 0.33 this 
phenomenon could not be observed any longer (Fig. 21). 
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Figure 21: NO formation of stimulated Caco-2 cells in presence of G. duodenalis 
trophozoites 
Differentiated Caco-2 cells (seeded in a 12-well tissue culture plate) were infected with (A) three times more 
trophozoites of the laboratory strain WB-C6 or different patient isolates or (B) three times less parasites than 
cells. In parallel, cells were stimulated or not with 25 ng IL1-β/well, 50 ng TNF-α/well and 50 ng IFN-γ/well. 
After 28 h cell-free supernatants were taken and total nitrite was measured in a colorimetric assay. 
Nonstimulated cells were not able to produce NO in detectable amounts. Each bar represents the mean ± SD of 
three technical replicates. 
 
 
4.3 Functional analysis of native and recombinant ADI of different G. duodenalis strains  
 
G. duodenalis is divided into different assemblages, where assemblage A and B are known to 
be pathogenic for humans. Until now, it remains unclear why progression of Giardia infection 
differs from patient to patient and if this is related to the different genotypes. To explore the 
pathogenesis of human giardial infections, investigations of factors involved in pathogen’s 
virulence are important. 
Among environmental isolates, virulence factors can vary in their nucleotide sequence. Such 
genomic variations can lead to amino acid exchanges that influence the tertiary and 
quaternary structure of the protein or its posttranslational modification. In case of enzymes, 
these modifications can lead to a partial or complete loss of its activity, especially when the 
active center is affected. 
Due to G. duodenalis genome sequencing of the different genotypes A, B and E, first hints 
exist that amino acid sequence variants of ADI occur. To which extent these variations 
influence the enzymatic activity is still unclear. In the following the hypothesis that 
G. duodenalis ADI as a potential virulence factor has differences in its enzyme activity profile 
that are related to diversity in its gene sequence was investigated. Therefore, it was necessary 
to characterize and compare both the recombinant and the native enzyme. 
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4.3.1 Establishment of a Giardia biobank as source for functional analyses 
   
Basis for upcoming experiments was the availability of G. duodenalis strains isolated from 
human biological samples. Therefore, the Giardia biobank established by the working group 
served as resource. It stored biomaterial in combination with medical information (e.g. 
patient’s health status, therapeutic response) to create a tool for functional epidemiology of 
G. duodenalis infections. To generate this biobank, Giardia positive human fecal samples 
were collected in cooperation with the Charité Berlin (Institute for Tropical Medicine).  In a 
routinely executed working procedure (technicians work), cysts were isolated and used to 
prepare genomic DNA for subsequent genotyping via sequencing and for excystation and 
limiting dilution. The limiting dilution was necessary to prevent mixtures of different 
G. duodenalis strains that can occur within biological samples and thus to obtain clonal 
trophozoite cell lines (Fig. 22) that could be used to for the functional assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Overview about the structure of the Giardia biobank 
 
 
 
The isolation of cysts and subsequent generation of viable clonal trophozoite cell lines was 
difficult. Despite cyst DNA was genotyped in 78% of the cases as assemblage B, only 
trophozoites of assemblage A survived indicating that culture conditions preferentially 
supported growth of parasites from this genotype. Also the cultivation of another 
Results 
83 
 
laboratory G. duodenalis strain (GS/M-H7), known to belong to the genotype B, remained 
without any success. Finally, four clinical isolates named in the following 16-01/E1, 
11-04/E3, 14-03/F7 and 115-01/H2 were available for the planned functional analysis. All of 
them belong to the subassemblage AII and were compared to the laboratory strain WB-C6 
that belongs to the subassemblage AI (Tab. 7). 
 
 
4.3.2 Characterization of native and recombinant ADI of different (sub)genotypes 
 
After the availability of different G. duodenalis isolates was assured by the Giardia biobank, 
beside recombinant ADI of assemblage A also recombinant forms of assemblage B and E 
were prepared. Through G. duodenalis genome sequencing, the nucleotide and amino acid 
sequence of these ADI genotypes are available on databases like NCBI or GiardiaDB. Thus, 
it was possible to produce recombinant ADI of assemblage B and E without amplifying both 
genes from genomic DNA. Instead, by an external service, both genes were synthesized in a 
donor vector equivalent that allowed further processing with the StarGate
®
 cloning system 
after delivery. After transformation into the expression strain DH5αZ1, both recombinant 
proteins were purified, as described for ADI and ADIC424A, by affinity chromatography. 
Afterwards, successful purification was verified by SDS-PAGE (Fig. 23). Both enzymes were 
identical in size and purity like the purified recombinant ADI and ADIC424A. 
  
 
 
 
 
 
 
 
Figure 23: SDS-PAGE of purified recombinant ADI proteins of different assemblages 
Successful affinity purification of 5 µg recombinant ADI assemblage A (lane 1), ADI assemblage B (lane 2), 
ADI assemblage E (lane 3) and mutant form of ADI assemblage A (lane 4) was verified in SDS-PAGE after 
Coomassie staining. M: Marker. 
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In parallel, the expression of native ADI by the laboratory strain WB-C6 and the clinical 
isolates (16-01/E1, 11-04/E3, 14-03/F7 and 115-01/H2) being collected in the Giardia 
biobank was investigated in Western blot analysis. Thereby, similar amounts of ADI at 
~ 64 kDa were identified in all lysates (data not shown). So far, there is no information about 
(different) posttranslational modifications like phosphorylations of the various ADI 
subgenotypes. This needs to be answered in continuative experiments. 
For further functional analysis, it was tested whether the native ADI is also enzymatically 
active within the G. duodenalis lysates like the purified, recombinant one. Due to the fact that 
trophozoites were counted before preparing the G. duodenalis lysates, the specific activity, 
expressed as U per trophozoites, of ADI was determined for all strains (Tab. 16). Finally, the 
enzymatic activity of G. duodenalis ADI was confirmed to be almost identical in all prepared 
lysates which were then used for further characterization.  
 
Table 16: Verification of specific ADI activity in lysates of different G. duodenalis strains 
For subsequent ADI activity determination, three independent lysates for each parasitic strain were prepared. 
U is defined as µmol substrate/min at 37°C in Hepes buffer. 
G. duodenalis strain Specific activity (U/10
6
 trophozoites) 
WB-C6 0.016 ± 0.003 
16-01/E1 0.006 ± 0.002 
11-04/E3 0.010 ± 0.007 
14-03/F7 0.008 ± 0.003 
115-01/H2 0.012 ± 0.003 
 
 
4.3.2.1 Determination of Km values from native and recombinant ADI 
 
The activity profile of enzymes involved in pathogen’s virulence can differ between strains. 
To find further hints for ADI to be involved in G. duodenalis virulence, the enzyme kinetic of 
different genotype variants was characterized. A simple model for the analysis of enzyme 
kinetics is the Michaelis-Menten theory. It assumes that in an enzymatic reaction substrate 
and enzyme form an enzyme-substrate complex. The substrate is then catalytically converted 
and the complex disaggregates into a free product and the enzyme. Enzyme-catalyzed 
reactions are saturable and show a hyperbolic curve progression. This saturation curve is 
formed due to the fact that at low substrate concentrations the active centers of the enzymes 
are predominantly available for substrate binding. Thus, the reaction rate can increase linearly 
with the substrate concentration. However, at high substrate concentrations nearly all of the 
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free enzyme binding sites are occupied. The reaction rate approximates its theoretical 
maximum (Vmax) given by the enzyme and does not longer increase. To determine the 
substrate affinity of an enzyme in an enzymatic reaction, the Michaelis constant (Km) is 
calculated. The Km value is defined as substrate concentration at which the reaction rate is half 
maximal (Vmax). The Km value is independent from the enzyme concentration whereas the 
maximal reaction velocity proportionally depends on it. A higher Km value reflects a higher 
substrate concentration necessary to reach Vmax/2. Thus, the higher the Km value, the lower is 
the affinity of an enzyme to a certain substrate. In enzyme kinetics, the Km value is obtained 
by using constant reaction conditions but varying the substrate concentration and subsequent 
direct-linear plotting of substrate concentration against reaction rate (Müller-Esterl, 2004). In 
this study, first the Km value of native ADI from different G. duodenalis strains was 
determined. Therefore, prepared lysates were directly used in the enzyme kinetic assay and 
subsequently the Km value was computed with GraphPAD software. Representatively, one 
graph is shown in Fig. 24A. The comparison between native ADI of different G. duodenalis 
strains revealed variations in the Km values among the subgenotypes. The ADI of lysates 
prepared from the laboratory strain WB-C6 (that belongs to assemblage AI) showed with 
0.25 mM ± 0.06 an at least three times lower Km value compared to the ADI of all other 
clinical isolates (that are of assemblage AII), i.e. the ADI of the laboratory strain WB-C6 had 
the highest affinity for arginine as substrate (Fig. 24B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Comparison of Km values from native ADI of different G. duodenalis strains 
(A) To determinate the Km value of native ADI, lysates of different parasitic strains were incubated with 
increasing concentration of arginine as substrate.  To calculate the Michaelis constant, the rate of citrulline 
formation was plotted against the various substrate concentrations, here shown for lysates of the laboratory strain 
WB-C6. (B) summarizes the obtained Km values for all native ADIs. Data for each strain represent mean ± SD of 
three independent experiments (paired (two-tailed) t test with *, P < 0.05; **, P < 0.01). 
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Next, the Km value of recombinant ADI of different assemblages was determined. For this 
purpose, purified enzymes as well as lysates of bacteria overexpressing the recombinant ADI 
variants were used in the enzyme kinetic assay. Interestingly, the Km value of the recombinant 
ADI of assemblage A was two times higher compared to the native ADI of the laboratory 
strain WB-C6, although both were identical in their amino acid sequence. Nevertheless, the 
computation of the Km values revealed differences in substrate affinity between the different 
recombinant ADI assemblages (Fig. 25). The ADI of assemblage A and E had a higher 
affinity than the enzyme of assemblage B. This is in accordance to the fact that assemblage A 
and E are more closely related in their amino acid identity.  
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Comparison of Km values from recombinant ADI of different assemblages 
For determination of the Km value of recombinant ADI from different genotypes (assemblage A, B and E), 
likewise both purified enzyme and lysates of DH5αZ1 cells overexpressing the enzymes were incubated with 
increasing concentration of arginine as substrate.  Calculation of the Michaelis constant was identical to that 
described in Fig. 24. Data for each strain represent mean ± SD of six independent experiments (paired (two-
tailed) t test with **, P < 0.01). Ass: assemblage. 
 
 
4.3.2.2 Analysis of the amino acids sequence from native and recombinant ADI 
 
The next step was to investigate if the noticed differences in substrate affinity of recombinant 
and native ADIs are related to the diversity in their amino acid sequence and in consequence 
to a diversity in their protein structure. So far, no crystal structure of the G. duodenalis ADI 
has been determined. However, there exist homologues of the enzyme in other organism like 
bacteria that have been crystallized and thus could be used as template for in silico three-
dimensional protein structure prediction. Thereby, the target protein is screened within a 
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liberty for an adequate template protein of know structure to perform a sequence alignment 
for subsequent modeling (Bordoli et al., 2009). The Web-based program ‘SWISS-MODEL’ 
(http://swissmodel.expasy.org/) enables such a comparative method and was therefore applied 
for protein modeling of G. duodenalis ADI (Guex and Peitsch, 1997; Schwede et al., 2003; 
Arnold et al., 2006). The protein model of G. duodenalis ADI (assemblage A) was generated 
on the basis of the structure known for ADI of Pseudomonas aeruginosa (Galkin et al., 2005) 
and is shown in Fig. 26. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: 3D model of G. duodenalis ADI (assemblage A) by SWISS-MODEL 
The homology model was built as single chain and its reliability was visualized by a color gradient from blue 
(representing more reliable regions) to red (representing potentially unreliable regions). 
 
 
Protein modeling predicted a complex folding structure of ADI (assemblage A) with several 
α-helices and β-sheets. Unfortunately, the target and template sequences were highly diverse. 
Thus, model quality for all three assemblages was indicated as poor. As alternative, to 
compare protein structures of different G. duodenalis ADI variants, a secondary structure 
prediction with the online server “PSIPRED” choosing PSIPRED v3.3 as prediction method 
(Jones, 1999) was performed. The analysis is based on a multiple sequencing profile for the 
target sequence by PSI-Blast (McGuffin et al., 2000). In comparison to multiple sequence 
alignment in standard protein-protein BLAST, PSI-BLAST  has the advantage to find more 
distantly related sequences and therefore is more sensitive (Altschul et al., 1997). The 
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secondary structure prediction for the different assemblages of ADI (Fig. 27) revealed a high 
frequency of secondary structure elements confirming the results of the previous performed 
three-dimensional protein modeling. Interestingly, due to their differences in the amino acid 
sequence, the overall number and position of α-helices and β-sheets varied between the 
assemblages. If and which structure alterations of ADI influence its enzymatic activity is not 
known so far and thus should be investigated in further experiments. 
 
 
 
 ADI assemblage A: 
 
 
 ADI assemblage B: 
 
 ADI assemblage E: 
 
 
Figure 27: Secondary structure prediction of G. duodenalis ADI variants by PSIPRED 
Feature predictions are highlighted onto the sequence as follows: yellow = sheet, pink = helix, noncolored = coil. 
 
 
Next step was to investigate whether there were differences in the amino acids sequence of 
ADI between patient isolates and the laboratory strain WB-C6 that might be responsible for 
the variation in substrate affinity. To determine the sequence variability of ADI in strains of 
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different subgenotypes, the ArcA gene was amplified from genomic G. duodenalis DNA, 
sequenced and translated to generate a multiple protein sequence alignment using ClustalW 
that is shown in Fig. 28. It was noticeable that there exist several amino acid alterations 
between the subgenotypes AI and AII of ADI that could explain the obtained differences in 
the Km values. But also differences in the ADI amino acid sequence within the subgenotype 
class AII was observed by comparing results obtained for the 115-01/H2 strain with the other 
clinical isolates at amino acid position 448.  
It is of interest whether the exchange of amino acids in the ADI primary structure can 
influence potential posttranslational modification, e.g. phosphorylation, and therefore can 
directly or indirectly change its activity. Thus, the web programs NetPhos 2.0 Server 
(http://www.cbs.dtu.dk/services/NetPhos/) was used to predict for serine, threonine and 
tyrosine phosphorylation sites (Blom et al., 1999) in G. duodenalis WB-C6 ADI. The 
obtained phosphorylation prediction sites were then compared to the amino acid changes in 
the ADI sequence of the clinical isolates that belong to the subgenotype AII. This comparison 
revealed that amino acids potentially important for phosphorylation of the enzyme were not 
exchanged. However, in case of serine that was predicted to be phosphorylated at amino acid 
position 495, an amino acid in the direct surrounding is altered in the subgenotype AII (data 
not shown). Furthermore, the comparison of predicted phosphorylation site between the 
known protein sequences of ADI assemblage A, B and E that are published in databases show 
clearly differences in their posttranslational modification pattern (data not shown). If this in 
consequence leads to changes in functional characteristics of the enzyme is not clear, and 
should be further investigated. 
To sum up, the analysis of the amino acids sequence from native and recombinant ADI give 
first hints that its differences in substrate affinity could rely on amino acid sequence variants 
within different (sub)genotypes. However, a definite link of patient’s symptoms to functional 
differences and amino acid variations in ADI is so far not evident. 
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 16-01/E1      MTDFSKDKEKLAQATQGGENERAEIVVVHLPQGTSFLTSLNPEGNLLEEPICPDELRRDH 60 
 115-01/H2     MTDFSKDKEKLAQATQGGENERAEIVVVHLPQGTSFLTSLNPEGNLLEEPICPDELRRDH 60 
 WB-C6         MTDFSKDKEKLAQATQGGENERAEIVVVHLPQGTSFLTSLNPEGNLLEEPICPDELRRDH 60 
               ************************************************************ 
 
 16-01/E1      EGFQAVLKEKGCRVYMPYDVLSEASPAEREVLMDQAMASLKYELHATGARITPKMKYCVS 120 
 115-01/H2     EGFQAVLKEKGCRVYMPYDVLSEASPAEREVLMDQAMASLKYELHATGARITPKMKYCVS 120 
 WB-C6         EGFQAVLKEKGCRVYMPYDVLSEASPAEREVLMDQAMASLKYELHATGARITPKMKYCVS 120  
               ************************************************************ 
 
 16-01/E1      DEYKRKVLSALSTRNLVDVILSEPVIHLAPGVRNTALVTNSVEIHDGNNMVFMRDQQITT 180 
 115-01/H2     DEYKRKVLSALSTRNLVDVILSEPVIHLAPGVRNTALVTNSVEIHDGNNMVFMRDQQITT 180 
 WB-C6         DEYKRKVLSALSTRNLVDVILSEPVIHLAPGVRNTALVTNSVEIHDSNNMVFMRDQQITT 180 
               ********************************************** ************* 
 
 16-01/E1      RRGIVMGQFQAPQRRREQVLALIFWKRLGARVVGDCREGGPHCMLEGGDFVPVSPGLAMM 240 
 115-01/H2     RRGIVMGQFQAPQRRREQVLALIFWKRLGARVVGDCREGGPHCMLEGGDFVPVSPGLAMM 240 
 WB-C6         RRGIVMGQFQAPQRRREQVLALIFWKRLGARVVGDCREGGPHCMLEGGDFVPVSPGLAMM 240 
               ************************************************************ 
 
 16-01/E1      GVGLRSTYVGAQYLMSKDLLGTRRFAVVKDCFDQHQDRMHLDCTFSVLHDKLVVLDDYIC 300 
 115-01/H2     GVGLRSTYVGAQYLMSKDLLGTRRFAVVKDCFDQHQDRMHLDCTFSVLHDKLVVLDDYIC 300 
 WB-C6         GVGLRSTYVGAQYLMSKDLLGTRRFAVVKDCFDQHQDRMHLDCTFSVLHDKLVVLDDYIC 300 
               ************************************************************ 
 
 16-01/E1      SGMGLRYVDEWIDVGADAVKKAKSSAVTCGNYVLAKANVEFQQWLSENGYTIVRIPHEYQ 360 
 115-01/H2     SGMGLRYVDEWIDVGADAVKKAKSSAVTCGNYVLAKANVEFQQWLSENGYTIVRIPHEYQ 360 
 WB-C6         SGMGLRYVDEWIDVGADAVKKAKSSAVTCGNYVLAKANVEFQQWLSENGYTIVRIPHEYQ 360 
               ************************************************************ 
 
 16-01/E1      LAYGCNNLNLGNNCVLSVHQPTVDFIKADPAYISYCKSNNLPNGLDLVYVPFRGITRMYG 420 
 115-01/H2     LAYGCNNLNLGNNCVLSVHQPTVDFIKADPAYISYCKSNNLPNGLDLVYVPFRGITRMYG 420 
 WB-C6         LAYGCNNLNLGNNCVLSVHQPTVDFIKADPAYISYCKSNNLPNGLDLVYVPFRGITRMYG 420 
               ************************************************************ 
 
 16-01/E1      SLHCASQVVYRTPLAPAAVKACEQEGDGVAAIYEKNGEPVDAAGKKFDCVIYIPSSVDDL 480 
 115-01/H2     SLHCASQVVYRTPLAPAAVKACEQEGDEVAAIYEKNGEPVDAAGKKFDCVIYIPSSVDDL 480 
 WB-C6         SLHCASQVVYRTPLAPAAVKACEQEGDGIAAIYEKNGEPVDAAGKKFDCVIYIPSSVDDL 480 
               ***************************  ******************************* 
 
 16-01/E1      IDGLKINLRDDAALSREIIADAYGLYQKLVSEGRVPYITWRMPSMPVVSLKGAAKAGSLK 540 
 115-01/H2     IDGLKINLRDDAALSREIIADAYGLYQKLVSEGRVPYITWRMPSMPVVSLKGAAKAGSLK 540 
 WB-C6         IDGLKINLRDDAAPSREIIADAYGLYQKLVSEGRVPYITWRMPSMPVVSLKGAAKAGSLK 540 
               ************* ********************************************** 
 
 16-01/E1      AVLDKIPQLTPFTPKAVEGAPAAYTRYLGLEQADICVDIK 580 
 115-01/H2     AVLDKIPQLTPFTPKAVEGAPAAYTRYLGLEQADICVDIK 580 
 WB-C6         AVLDKIPQLTPFTPKAVEGAPAAYTRYLGLEQADICVDIK 580 
               **************************************** 
 
Figure 28: Amino acid alignment of native ADI variants from different 
G. duodenalis strains 
The amino acid differences in the ADI sequences of clinical isolates and the laboratory strain WB-C6 were 
highlighted in yellow. Because of having an identical sequence, 16-01/E1 is shown representatively for 11-04/E3 
and 14-03/F7. 
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5 Discussion 
 
Giardiasis is one of the most prevalent parasitic diseases worldwide. Its causative agent 
G. duodenalis infects human and other mammals that in consequence can suffer from 
intestinal malabsorption and (chronic) diarrhea. Giardial infections influence humans in two 
ways: directly by being a major public health concern in developing and developed countries, 
and indirectly by constituting an economical problem e.g. when livestock, like cattle, are 
affected.  
So far, no vaccine against human giardiasis is available. In the past, it was tried to immunize 
domestic animals with commercial available or self-prepared veterinary vaccines. Subsequent 
experimental infections of kittens showed that vaccination does not prevent infection but 
reduces intensity of symptoms and secretion of cysts (Olson et al., 1996). However, this 
partial success of vaccination was rebutted for other animals like calves (Uehlinger et al., 
2007). To cure G. duodenalis infections several drugs are administered. Unfortunately, in 
humans treatment failures, e.g. due to development of resistance, occur. Additionally, patients 
often have a bad compliance caused by several side effects like acid regurgitation and nausea 
(Upcroft and Upcroft, 1993; Lalle, 2010). Thus, the development of new treatment or 
prevention strategies is indispensable. One possibility to find new drug targets is the 
identification of virulence factors. To date, certain Giardia-induced mechanisms that enable 
the parasite to handle or evade the host’s immune systems are described. Furthermore, also 
factors that are potentially involved in parasite virulence, like the G. duodenalis ADI, were 
noticed. For the treatment of giardiasis the G. duodenalis ADI is an interesting parasite-
specific target for the design of new drugs because its expression is limited to the parasite, it 
catalyzes the first step in the parasite’s energy metabolism and it seems to be involved in host-
parasite interplay (Ankarklev et al., 2010; Rópolo and Touz, 2010).  
The aim of this study was to find distinct hints that confirm the role of G. duodenalis ADI as a 
virulence factor. Therefore, the enzyme’s genetic diversity and its role in host-parasite 
interaction were analyzed. The impact of recombinant G. duodenalis ADI on DC initiating 
host’s adaptive immune response was investigated. Furthermore, the influence of viable 
parasites expressing native G. duodenalis ADI on epithelial cells that serving as guardians of 
the mucosal immunity was studied. By sequencing and enzyme kinetics of both, native and 
recombinant G. duodenalis ADI, a potential link between substrate affinity and genotypic 
diversity was investigated.    
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5.1 G. duodenalis ADI is involved in host-pathogen interplay 
 
One strategy of several pathogens to evade immune effector mechanisms is to deplete 
arginine with microbial enzymes. As part of their virulence mechanisms, these enzymes often 
compete with the host enzymes for the same substrate leading to a limited immunological 
response. An intensively studied example is the arginine-depleting enzyme arginase that is 
expressed by pathogens to compete for arginine with the host’s NOS to prevent the formation 
of anti-microbial NO (Bronte and Zanovello, 2005; Das et al., 2010). Another arginine-
metabolizing enzyme, the ADI, has been implicated in virulence of several other microbes 
like Streptococcus, Mycoplasma and Listeria (Gong et al., 1999; Benga et al., 2004; Ryan et 
al., 2009; Fulde et al., 2011). Which impact the enzymatic activity of G. duodenalis ADI, that 
means the consumption of arginine to form citrulline and ammonia, has on host defense 
mechanism is less understood and thus was investigated. The results of this study shall be 
discussed in the following.   
 
 
5.1.1 Interaction between G. duodenalis ADI and human moDC 
 
5.1.1.1 Usage of human moDC as host cells 
 
As linker between innate and adaptive immune response, DC are important in pathogen 
clearance mechanism. As described, they are able to control the gut lumen with their dendrites 
and thereby can come into close contact with parasites like Giardia during an infection. To 
date, only two studies with murine cells have been published that investigated the interaction 
of Giardia parasites with DC (Kamda and Singer, 2009; Kamda et al., 2012). These studies 
revealed that DC are critical for clearance of Giardia infections in mice and that the parasite 
has the ability to modulate their function.  
Prior studying the interaction of Giardia with DC, several experimental conditions were 
pondered for the following reasons. To generate a surrounding that is related those in human 
infections and to ensure that enough cells were available for the planned experiments, it was 
decided to generate and use DC from human moDC. This moDC were stimulated with 
different concentrations of LPS, because treatment with recombinant enzyme alone did not 
lead to DC activation. Interestingly, also a previous study has shown that Giardia extracts or 
live trophozoites were found to weakly activate mouse DC (Kamda and Singer, 2009). For 
investigation of host-parasite interplay, DC were treated with recombinant enzyme instead of 
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live Giardia trophozoites. This was done for several reasons. First, moDC grow in suspension 
and thus do not form a monolayer where Giardia trophozoites can attach, second both cell 
types have different oxygen requirements, and third it is not clear whether trophozoites 
release and to which extent G. duodenalis ADI in absence of IEC. An alternative would be the 
usage of G. duodenalis lysates as it was done by Kamda and Singer (2009). However, in this 
case it cannot be excluded that other factors than ADI lead to a resultant DC phenotype or if 
these factors influence the ADI function.  
 
 
5.1.1.2 Consequences of moDC treatment with G. duodenalis ADI 
 
G. duodenalis ADI was shown to modulate cell surface markers and cytokine response of 
in vitro activated human moDC. In the past, studies illustrated that especially cytokines are 
necessary in host defense against Giardia (Bienz et al., 2003; Zhou et al., 2003; Zhou et al., 
2007). In this report, determination of several pro- and anti-inflammatory cytokine revealed a 
cytokine-specific influence of ADI that resulted in an impaired secretion of IL-10 and 
IL-12p40 and increased levels of TNF-α compared to untreated DC. The release of cytokines 
is a complex immunological network where single components depend on each other, e.g. it is 
known that anti-inflammatory IL-10 suppresses the production of pro-inflammatory TNF-α 
(Armstrong et al., 1996; Williams et al., 2004). Thus, the observed increased TNF-α release 
might be a consequence of impaired IL-10 release. Children suffering from symptomatic 
giardiasis were shown to have increased mucosal levels of pro-inflammatory cytokines 
including TNF-α, which decreased after anti-parasitic treatment and resolution of symptoms 
while local levels of IL-10 increased after treatment (Maciorkowska et al., 2005). This is in 
agreement with the in vitro findings of this study and may indicate that ADI activity impairing 
IL-10 and enhancing TNF-α secretion by mucosal DC could underlay the in situ observation 
in samples from these children. The relative abundance of IL-10 and TNF-α is recognized as a 
critical parameter in intestinal diseases in mice (Kontoyiannis et al., 2001) and humans 
(Glocker et al., 2011; Ordás et al., 2012). Another report, correlating with the results of this 
study, identified increased serum levels of TNF-α in Turkish children infected with 
G. duodenalis. After treatment with MTZ, patients became free of parasites and cytokine level 
returned to normal state (Bayraktar et al., 2005). Additionally, Kamda and Singer (2009) 
recognized small amount of TNF-α after stimulation of mouse bone marrow-derived DC with 
live Giardia trophozoites and Giardia extracts. 
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After release of ADI, which function does the increasing TNF-α secretion and the arginine 
depletion and formation of ammonia and citrulline have for the parasite? Arginine-dependent 
response modulation would be consistent with observations on the pathophysiology of human 
giardiasis. Atrophy of villi has been detected microscopically in intestinal biopsies of 
chronically infected patients, and symptomatic disease has been correlated with a dysfunction 
of the epithelial barrier (Troeger et al., 2007) but the process leading to this is not yet 
understood. These sequelae can, however, also be observed when a human intestinal epithelial 
cell line is treated with TNF-α (Schmitz et al., 1999). TNF-α may thus have pathogenic 
properties in this context. Studies in mice showed that peak level Giardia parasite loads were 
around 10-fold higher in animals devoid of TNF-α (Zhou et al., 2007) hence it was proposed 
that it has a protective function in giardiasis. However, in the same study transepithelial 
resistance was reduced to the same extent despite a much lower parasite burden in TNF-α 
responsive mice. An explanation consistent with the results from human epithelial cell line 
exposed to TNF-α (Schmitz et al., 1999) could be that reduced epithelial integrity during 
giardiasis is due to parasite factors and TNF-α, the latter exerting a dual (protective and 
pathogenic) role. Interestingly, beside ADI also OCT (the next enzyme in the ADH pathway) 
is released by the parasite in contact with intestinal cells in vitro (Ringqvist et al., 2008) and 
was detected, like ADI, to be an immunodominant antigens during infection (Palm et el., 
2003; Téllez et al., 2005). This indicates that significant amounts of both enzymes are found 
extracellular and therefore free citrulline generated by ADI may even be further metabolized 
to ornithine by OCT. It is tempting to speculate that this may exacerbate TNF-α production 
because the negative feedback of citrulline (which was observed in this study) on this 
parameter would be reduced. Thus, release of ADH compounds could have evolved in part 
due to selective pressure by the host’s immune response. 
Another observation of this study was that the expression of the surface molecules CD86 and 
CD83 was impaired after treatment of LPS-activated moDC with ADI. The reduction of 
CD86 was also seen by Kamda and Singer (2009) after treatment of LPS-stimulated murine 
bone marrow-derived DC with Giardia extract. If the parasite, in addition to ADI, possess 
several other immunomodulatory factors is unclear and further studies are needed to identify 
their molecular nature. Nevertheless, it is conceivable that the parasite actively changes DC 
function to negatively influence the activation of the host’s adaptive immune response. Intact 
cell-cell interplay between APC and T cells is indispensable, especially during giardial 
infection where T cells were indicated to be involved in parasite elimination. 
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5.1.1.3 Reasons for immunomodulation of moDC by G. duodenalis ADI 
 
Although DC are important for adaptive immunity against microbial infections, the effect of 
pathogen-mediated arginine depletion on their function is not clear yet. It is known, that 
arginine-dependent virulence mechanisms of pathogens rely on enzymes such as arginases or 
deiminases that deplete arginine but also generate reaction products at the same time. Of note, 
these products differ between these classes of enzymes that generate ornithine and urea or 
citrulline and ammonia, respectively. Commonly, changes of immune cell responses due to 
different arginine levels have been studied by comparing responses in the presence or absence 
of arginine. However, this does not reflect the situation when arginine is depleted by an 
enzymatic reaction as it can be the case during infections. Yet, the combined effect of arginine 
depletion by an enzymatic reaction and the ensuing product formation on immune cells has 
largely been ignored. Thus, after monitoring the immunomodulatory effects on in vitro 
activated human moDC after treatment with recombinant ADI, it was tested whether 
arginine depletion and/or the generated reaction products citrulline and NH4
+
 are responsible 
for the obtained phenotype. It was recognized in this study, that DC modulation of cell surface 
markers and cytokine response required parasite enzyme activity and the effects depend on 
both, depletion of arginine and the ADI reaction products, in particular NH4
+
. This was the 
first time showing an immunomodulatory effect of arginine depletion and NH4
+
 formation on 
the response of DC other than on NO formation known from other pathogens like 
Helicobacter pylori (Gobert et al., 2001) and Leishmania spp. (Gaur et al., 2007) that rely on 
the action of arginases.  
As mentioned before, both arginases and ADI have been associated with pathogen virulence. 
Both deplete arginine but their reaction products ornithine/urea and citrulline/NH4
+
 differ. In 
this work it was noticed that NH4
+
 but not urea exacerbated the inhibition of IL-10 production 
and surface marker upregulation compared with arginine depletion alone. These findings 
suggest a difference between the products of arginases and deiminases with respect to their 
potency of modulating human moDC cytokine secretion and surface marker expression. More 
widely, it can be hypothesized that pathogens have evolved diverse arginine-dependent 
immunomodulation mechanisms. Of note, ADI homologues have been implicated in the 
virulence of Streptococci isolates (Fulde et al., 2011) affecting intracellular survival of the 
bacteria (Benga et al., 2004) and inhibiting proliferation of PBMC in vitro (Degnan et al., 
1998). It will be interesting to investigate whether ADI in the case of these bacterial infections 
has similar extended immunomodulatory activity as described here for G. duodenalis ADI. 
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In this study, the reduction of surface located CD83 correlated with an inhibition of the 
mTOR pathway since phosphorylation of the mTOR S6K target protein was decreased after 
treatment of DC with G. duodenalis ADI. Precedence for a clinically relevant role of amino 
acids in modulating immune responses exists (Evoy et al., 1998; Calder, 2006). Thereby, for 
example arginine is not only necessary for generation of NO but it plays also other important 
roles during immune response. Lack of arginine was shown to inhibit T-cell function 
(Zea et al., 2004), and arginine levels affect signaling via the mTOR pathway as reported for 
other cells (Ban et al., 2004; Yao et al., 2008).  So far, the role of arginine for mTOR 
signaling in DC is not known. However, for DC it has been shown that branched-chain amino 
acids affect maturation, and it has been proposed that this modulation is a consequence of 
inhibition of the mTOR pathway (Kakazu et al., 2007). The results of this study are consistent 
with this hypothesis but extend the concept to arginine. Of note, NH4
+
 has recently been 
reported to modulate mTOR activity in yeast cells (Santos et al., 2012). This suggests that 
reaction products formed by arginine-depleting enzymes could further affect mTOR signaling. 
However, additional signaling pathways are likely to be involved in mediating the distinct 
effects of arginine depletion alone and NH4
+
 formation. The latter has recently also been 
invoked in the T cell inhibition mediated by Salmonella L-asparaginase II (Kullas et al., 2012). 
Further studies are required to understand this comprehensively.  
To sum up, it was shown that enzymatic activity of G. duodenalis ADI modulates surface 
markers and cytokine response of in vitro activated human moDC. It is suggested that the 
resultant impaired IL-10 and enhanced TNF-α secretion plays a central role in pathogenesis 
and that the reduced upregulation of surface CD83 and CD86 molecules, partially caused due 
to inhibition of the mTOR signaling pathway, can influence the adaptive immune response. 
These alterations of DC function were identified to depend on both, depletion of arginine and 
the ADI reaction products, in particular NH4
+
. That arginine depletion may indeed occur 
in situ by release of ADI was calculated here and thus the ability to modulate DC function 
could provide a selective advantage to the parasite. Furthermore, the comparison of NH4
+
 and 
urea revealed distinct immunomodulatory activities for these products of deiminases and 
arginases, respectively. These data implicate that arginine-metabolizing enzymes of pathogens 
are more widely involved in immunomodulation of DC and suggest distinct roles for the 
reaction products of different enzyme classes in this process. This observation can contribute 
to the general understanding of arginine-dependent virulence mechanisms of pathogens. 
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5.1.2 Interaction between G. duodenalis ADI and Caco-2 cells 
 
Structures and functions of mucosal immunity are complex. So far, the communication 
between Giardia as parasite and IEC as well as DC as host cells is less understood. 
Evidences for the interaction of host and parasite were revealed in this study. It was observed 
that G. duodenalis was more aerotolerant in the presence of Caco-2 cells. This phenomenon 
was also recognized by Roxström-Lindquist et al. (2005) and was found during co-cultivation 
of tissue culture cells with other anaerobic bacteria (Claesson and Gotthardsson, 1988; Hosogi 
and Duncan, 2005). Additionally, Roxström-Lindquist et al. (2005) showed an induced 
secretion of CCL20, a chemokine being important for DC recruitment, by IEC after in vitro 
treatment of the cells with the parasite. Same results were obtained after contact of IEC with 
trophozoite-free medium from a Giardia culture indicating that secreted parasitic factor(s) are 
involved in upregulation of the chemokine response. That secreted Giardia factors can 
influence IEC function was given by Lee et al. (2012) showing that excretory-secretory 
products of the parasite are able to induce IL-8 production in HT-29 cells. As described, a 
known parasitic factor of G. duodenalis that is released in vivo and in vitro in the intestine is 
its ADI (Ringqvist et al., 2008). Microarray analysis of the parasitic transcriptional response 
to host cell contact revealed a transient upregulation of ADI mRNA levels within 1.5 h 
(Ringqvist et al., 2011). The observation that release occurs already within 15 min after 
contact of the parasite with Caco-2 cells (Ringqvist et al., 2008) was confirmed in this study. 
Furthermore, host induced release of ADI was identified to occur independent from the 
subassemblage by all investigated G. duodenalis strains and thus indicating its general role in 
host-parasite interaction. Commonly, eukaryotic secretory proteins are translocated by the 
endoplasmic reticulum (ER)-Golgi pathway to the cell surface and are released there into the 
extracellular space (Nickel, 2003). G. duodenalis lacks an intact ER/Golgi system and its ADI 
does not contain a classical signal peptide being necessary for this route. In future, it needs to 
be investigated whether the release of the enzyme is mediated by unconventional protein 
export, e.g. by formation of exosomes, as known for other proteins (Nickel, 2003). 
Release of ADI is also known from other microbes like Streptococcus (Christopher et al., 
2010), but its function in context with giardiasis is not understood yet. It is supposed that the 
resultant arginine depletion and formation of reaction products by enzymatic active 
G. duodenalis ADI influences the immunological function of IEC and thus is involved in 
disease mechanism. Reduced NO production in consequence of arginine depletion by 
pathogenic upregulation of host arginases was observed in several infectious diseases (Lahiri 
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et al., 2008; Lewis et al., 2010; Andrade et al., 2012). Also other arginine-depleting enzymes 
as the recombinant Mycoplasma ADI were shown to negatively affected the NO formation in 
macrophages in vitro (Noh et al., 2002). In vitro investigations of G. duodenalis WB-C6 
(Eckmann et al., 2000) as well as its recombinant ADI (Ringqvist et al., 2008) revealed 
inhibition of NO formation of human IEC by consumption of free arginine. Additionally, this 
study identified that G. duodenalis strains of another subgenotype than the laboratory strain 
WB-C6 were able to reduce NO to a similar extent. As NO is known to disturb differentiation 
and growth of Giardia (Eckmann et al., 2000), it seems to be that arginine consumption by 
ADI to prevent its formation by the host is an alternative to the upregulation of host arginases 
and used as general defense mechanism by the parasite.  
Beside reduction of NO formation, arginine depletion by G. duodenalis ADI led to reduced 
proliferation of human IEC lines in vitro (Stadelmann et al., 2012). This ability of ADI to 
inhibit growth was also shown for Mycoplasma-infected cells, e.g. tumor cell lines, indicating 
a complex role of the enzyme in disease mechanisms (Miyazaki et al., 1990; Takaku et al., 
1992). To further investigate the multiple function of ADI in giardiasis, the communication 
between IEC and DC during giardial infection should not be disregarded. Microarray analysis 
revealed an upregulation of the TNF-α receptor on IEC after contact with 
Giardia trophozoites in vitro indicating an activation of intestinal epithelium to respond to 
TNF-α (Roxström-Lindquist et al., 2005). In this study, an upregulation of TNF-α secretion 
was recognized by ADI-treated moDC in vitro. Although Li et al. (2006) described NOS-1 to 
be involved in the elimination of giardial infection in mice, this and other studies 
(Eckmann et al., 2000) showed that infection of human IEC cultures with G. duodenalis 
inhibits epithelial NO production under TNF-α stimulation. A linkage between TNF-α and 
NO was represented in Giardia independent study where rats were stimulated 
intraperitoneally with LPS. NO was upregulated in the duodenum by increasing levels of 
TNF-α. Interestingly, some of these rats developed diarrhea (Arya et al., 2000). This, in turn, 
could be a consequence of the increasing NO level as NO is discussed to be linked to 
secretion of water in the intestine (Mourad et al., 1999; Kukuruzovic et al., 2002). 
Here, it is suggested that there exists a linkage between DC response to G. duodenalis ADI 
and IEC function in giardiasis. This should be further investigated in an adequate in vitro or 
in vivo model where several cell types can be treated with G. duodenalis ADI in parallel. 
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5.1.3 Interaction between G. duodenalis ADI and host proteins 
 
Enzymes of mammals like human PADs are able to citrullinate intrapeptidic arginine in 
proteins. That kind of posttranslational modification can lead to an altered biological function 
of the affected protein or disrupt its interaction with other molecules. This was shown in the 
immunological context by Proost et al. (2008) where PAD purified from rabbit skeletal 
muscle citrullinated the chemokine CXCL8 and in consequence altered the neutrophil 
extravasation during inflammation. ADI-mediated citrullination of e.g. receptors of host 
immune cells would give Giardia the ability to immunomodulate and thus to escape the host 
immune response. Such a dual function of the enzyme to deiminate free and intrapeptidic 
arginine is known from the pathogen Porphyromonas gingivalis that causes periodontitis 
(Shirai et al., 2006; Rodríguez et al., 2009). Although no pad homologous genes have been 
found in the Giardia genome, Touz et al. (2008) revealed a PAD activity for 
G. duodenalis ADI. Although using the same reaction conditions, this result could not be 
confirmed in this study. That the parasite’s ADI cannot citrullinate intrapeptidic arginine was 
also shown by Li et al. (2009) and thus the results described here were in agreement with their 
in vitro test. The main difference and a possible explanation for the contrary results is that 
Touz et al. (2008) used ADI purified from G. duodenalis trophozoites in contrast to the here 
used purified G. duodenalis ADI expressed recombinantly in E. coli. In vivo overexpression 
in eukaryotes allowed potential posttranslational modification of the native ADI that might 
impact its function, whereas expression in bacteria did not. It remains unclear whether the 
observed PAD activity does really exist and, if so, whether it has physiologically relevance. 
 
 
5.2 G. duodenalis ADI has assemblage-associated genotypic and functional differences 
 
One characteristic feature of human giardial infection is its variable outcome among patients. 
It is discussed whether clinical symptoms are correlated to the assemblage type of the 
parasite. Several investigations describe infections with assemblage A parasites to be more 
severe than those with assemblage B parasites (Haque et al., 2005; Sahagún et al, 2008). 
Other studies showed assemblage B parasites to be more pathogenic (Homan and Mank, 
2001; Mohammed Mahdy et al., 2009). Controversially, Kohli et al. (2008) demonstrated both 
assemblage types to cause similar illness. Same results but with trends to certain symptoms, 
e.g. that assemblage AII was more often associated with abdominal pain, nausea and vomiting 
(Sarkari et al., 2012) or fever (Breathnach et al., 2010) and flatulence was linked to 
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assemblage B (Lebbad et al., 2011), were noticed by others. Additionally, experiments with 
Giardia-infected gerbils (Bénéré et al., 2012) and IEC (Koh et al., 2013) confirmed 
assemblage-specific differences in pathogenicity.  
Comparative genomic analyses were used to identify virulence factors for other pathogens 
(Sahl et al., 2013; Tang et al., 2013). Gene sequence alignment of G. duodenalis ADI revealed 
assemblage-specific differences being characteristically for a virulence factor. In detail, a 
nucleotide identity of 81% between A-B, 89% between A-E and 80% between B-E and an 
amino acid identity of 89% between A-B, 94% between A-E and 89% between B-E was 
determined. If G. duodenalis ADI, as potential virulence factors, has sequence-variability that 
leads to functional differences was investigated. Therefore, recombinant 
ADI (assemblage A, B and E) and the native enzyme (different subtypes of assemblage A) 
were genotypically and functionally characterized in this study. 
ADI is expressed by several microorganisms and was identified to be highly specific for 
arginine as substrate in the 1960s (Kihara and Snell, 1957; Petrack et al., 1957). Here, 
biochemical characterization of recombinant G. duodenalis ADI (assemblage A) revealed a 
Km value of 0.58 mM for arginine. In a similar range, Li et al. (2009) described a Km value of 
0.16 mM. The deviation can be explained by usage of different buffer and reaction conditions 
(pH, temperature). The determined Km value for G. duodenalis ADI was comparable to those 
observed for ADI of other microbes like Pseudomonas plecoglossicida with Km = 0.7 mM 
arginine (Zhu et al., 2010) or Burkholderia mallei with Km = 0.09 mM arginine (Li et al., 
2008). Comparison of native and recombinant G. duodenalis ADI (both WB-C6; 
assemblage AI) revealed a twofold difference in the Km value at the same reaction conditions. 
This might be due to (different) factors included in the used Giardia or E. coli lysate 
influencing the enzyme directly or indirectly. Furthermore, a threefold difference in substrate 
affinity between recombinant enzymes of assemblage A and E to B was detected. As 
assemblage A and E ADI are closer related in their amino acid sequence, a correlation 
between genotype and enzyme activity is indicated. The comparison of Km value of native 
ADI expressed by different G. duodenalis isolates revealed a subassemblage-specific 
difference in substrate affinity as well. That amino acid exchange in proteins results in 
changes of the Km value was shown for other microorganisms like Mycoplasma hominis 
where ADI mutation leads to a shift from 0.24 mM to 0.71 mM (Wei et al., 2007). In 
Pseudomonas aeruginosa the substrate affinity to arginine changed from 0.14 mM of the 
wild-type enzyme to 1.1-38 mM in mutant ADI’s (Lu et al., 2006).  
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It is assumed that the differences in Km values are correlated to the ADI sequence variations 
of the certain G. duodenalis strains. G. duodenalis ADI belongs to the guanidino group-
modifying enzyme superfamily, which conserves a Cys-, His-, and Asp-based catalytic core 
(Li et al., 2009). Further details of its three dimensional structure are less understood. It is 
important to investigate to which extent the amino acid differences between the individual 
(sub)assemblages influence the active site of the enzyme. Therefore, amino acid substitution 
in both, the native G. duodenalis ADI (transgenic parasites) and the recombinant enzyme 
should be performed.  
Posttranslational modifications are known to influence protein structure and function. For 
example, alteration of enzyme activity was shown in studies of Mesojednik and Legisa (2005) 
where activity of degraded 6-phosphofructo-1-kinase of Aspergillus niger was restored after 
induction of phosphorylation. Possible posttranslational modifications of G. duodenalis ADI 
are unclear. A previously described (Touz et al., 2008) higher-molecular-mass 85-kDa form 
of native G. duodenalis ADI, caused by sumoylation, could not be confirmed in this study. 
This does not exclude posttranslational modification of the parasite’s ADI at all. For this 
reason, it should be tested whether amino acids differences in ADI (sub)assemblages changes  
posttranslational modification patterns of the enzyme which in turn could influence its 
activity.  
 
 
5.3 Future perspectives 
 
This work revealed two major hints for ADI to be a (molecularly defined) virulence and 
pathogenicity factor of G. duodenalis and thus potentially disease-causing or at least involved 
in the establishment of the infection. First, recombinant G. duodenalis ADI as well as 
G. duodenalis ADI variants of clinical isolates (including the laboratory strain WB-C6) were 
identified to have substrate affinity differences probably caused through sequence variation. It 
is speculated, that the ADI activity might be related in this context to different disease 
outcome. Second, G. duodenalis ADI was identified to be immunomodulating. It was 
observed that as consequence of enzyme activity surface markers and cytokine response of 
in vitro-activated human moDC was changed. This depended on both, depletion of arginine 
and the ADI reaction products, in particular NH4
+
. By investigating the in vitro consequences 
of arginine depletion, it was recognized that the mTOR pathway is implicated in the 
molecular signaling process and leads in part to the modulation of DC response. Furthermore, 
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a modulating effect on the response of IEC was observed in vitro as well. 
G. duodenalis trophozoites of different clinical isolates reduced the NO formation of Caco-2 
cells, probably due to the consumption of arginine by the parasite’s ADI. Together with the 
observation that immunomodulation and arginine-metabolizing enzymes were also noticed to 
be implicated in pathogen’s virulence and immune evasion mechanisms in a broad range of 
other infections, the hypothesis of G. duodenalis ADI to be a virulence factor was 
strengthened. 
The relevance of these in vitro findings for the understanding of the pathogenesis of giardiasis 
must remain speculative at the moment. It can only be suggested that the modification of DC 
and IEC function by its ADI provides a selective advantage for the parasite to evade the host 
immune response. To clarify if this is also true in human infections, further studies are 
required. Thereby, the communication between different immune cells as response to a 
giardial infection should be considered.  For example, it would be interesting to investigate 
how T cells and IEC were affected by G. duodenalis ADI-modified DC in vivo. 
To study host-parasite interplay in giardial infections, in vivo animal models are necessary, 
but difficult to establish as e.g. infection of mice is limited to certain G. duodenalis strains 
(Solaymani-Mohammadi and Singer, 2011). Thus, an adequate in vitro model that is closer 
related to the in vivo situation should be established. An option might be the usage of 
intestine-like structures. Such organoids have been established from primary human intestinal 
tissue (Sato et al., 2011) and human induced pluripotent stem cells (Spence et al., 2011). 
These 3D structures do not reproduce the in vivo situation completely e.g. due to lacking 
immune cells, but give a well-differentiated intestinal epithelial tissue for in vitro 
investigations (Klotz et al., 2012). To further analyze the role of ADI in giardial infections, 
organoids can be treated with either recombinant or native enzyme. The latter can be used as 
purified enzyme from G. duodenalis trophozoites (of different assemblages) transiently 
overexpressing ADI or by directly adding these trophozoites. As negative control, an ADI 
knockdown in Giardia parasites should be generated (e.g. by antisense technique). As ADI is 
possibly essential for the parasite’s survival due to its role in ATP metabolism, a functional 
knockout of the enzyme should be avoided. The possibility to genetically manipulate the 
parasite was shown by Touz et al. (2008) who already overexpressed ADI in G. duodenalis. 
In continuing experiments, an alternative to trophozoites overexpressing ADI would be the 
use of cell culture supernatants from Giardia-treated Caco-2 cells containing the released 
native enzyme. However, the presence of other enzymes that were described to be released 
(e.g. enolase) by the parasite (Ringqvist et al., 2008) can be prejudicially. Another method 
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would be to infect mice with G. duodenalis trophozoites and to immunoprecipitate native ADI 
from the intestine by using the generated anti-Gd ADI antiserum. Thereby, the possibility that 
mice cannot be infected with all G. duodenalis strains has to be considered.   
Furthermore, for functional epidemiology it is necessary to augment the number of available 
G. duodenalis isolates of symptomatic and asymptomatic patients within the Giardia biobank. 
The more ADI variants can be by characterized on basis of epidemiological data, the higher 
the chance to identify a potential link between enzyme function and clinical pathology.  
 
Further investigation will show whether G. duodenalis ADI is a virulence factor and thus a 
potential new target for treatment strategies and drug design. If so, developing of 
G. duodenalis ADI inhibitors or supplementation of arginine, as shown for other parasitic 
infections (Castro et al., 2012), might be approaches to cure giardiasis.  
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7 Supplementary material 
 
7.1 Selbstständigkeitserklärung 
 
Hiermit bestätige ich, Stefanie Marek (geb. Banik), die Kenntnisnahme über die dem 
angestrebten Verfahren zugrunde liegende Promotionsordnung.   
 
Gemäß § 7 Absatz 3 der Promotionsordnung erkläre ich an Eides statt, dass ich die 
vorliegende Dissertation mit dem Titel „Giardia duodenalis arginine deiminase and its role in 
host-parasite interplay” selbstständig verfasst und keine anderen als die angegebenen Quellen 
und Hilfsmittel verwendet habe. 
 
Des Weiteren versichere ich, dass diese Dissertation nie Gegenstand eines früheren 
Promotionsverfahrens gewesen ist oder als ungenügend beurteilt wurde. 
 
Unter meiner Anleitung und Betreuung hat Anna-Luise Kluge ihre Bachelorarbeit 
„Herstellung und Charakterisierung von rekombinanten Giardia duodenalis 
Arginin-Deiminase-Proteinen verschiedener Genotypen“ in der Arbeitsgruppe von Herrn 
Dr. rer. nat. Aebischer (FG 16, Robert Koch-Institut) angefertigt. Ein Teil der daraus 
resultierenden Rohdaten wurden in meiner Dissertation verwendet. 
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